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c-JUN is a major component of the activator protein-1 transcription factor 
complex and its activation depends mainly on phosphorylation by the c-JUN 
amino-terminal kinases. c-JUN has been implicated in a wide range of 
physiological and pathological processes including development, regeneration 
and tumorigenesis. However the direct gene targets that mediate these specific 
processes remain to be investigated.  
To identify novel c-JUN targets, we performed whole genome expression 
array analyses from (1) viable embryos and (2) UV or cisplatin-treated 
primary mouse embryonic fibroblasts (MEFs) of mice carrying wild type c-
Jun (c-Jun+/+), knockout c-Jun (c-Jun-/-) or an amino-terminal 
nonphosphorylatable mutant form of c-Jun (c-JunAA/AA). We identified a large 
number of differentially expressed genes by comparing the gene expression 
profiles between c-Jun+/+ and c-Jun-/- samples. In contrast, we observed only a 
small number of differently expressed genes between c-JunAA/AA and c-Jun+/+ 
samples. These differentially expressed genes were then categorized as c-JUN 
amino-terminal phosphorylation (JNP)-dependent or -independent targets. Our 
data demonstrated that JNP is required only for a small subset of c-JUN target 
gene transcription. Furthermore, the differentially expressed genes were also 
classified into stress-dependent or -independent target groups, which revealed 
the presence of c-JUN-dependent genes that are regulated by stress factors, as 
well as a significant group that are regulated in a stress-independent manner. 
To explore novel c-JUN regulated biological processes, we analyzed the 
differentially expressed genes via Ingenuity Pathway Analysis, and the 
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Hepatic fibrosis/Hepatic stellate cell (HSC) activation was predicted to be the 
topmost affected pathway. Therefore, we assessed the activated HSC status in 
the embryos and detected dramatically high levels of activated HSCs in c-Jun-
/- embryos as compared to c-Jun+/+ embryos. This result again suggested an 
important role of c-JUN in hepatic fibrosis. To elucidate the role of c-JUN in 
hepatic fibrosis, we utilized the c-Jun conditional knockout mice to 
inactivate c-Jun in adult liver HSCs (1) and both hepatocytes and 
hematopoietic cells (2), by using Col-CreER and Mx-Cre transgenic mice 
respectively. Fibrosis was induced by chronic injections of carbon 
tetrachloride over time to adult mice and livers were harvested and 
analyzed for degree of fibrosis and HSC activation. Surprisingly, we observed 
that deletion of c-Jun in HSCs resulted in significantly more activated HSCs 
and more fibrosis whereas deletion of c-Jun in hepatocytes and hematopoietic 
cells resulted in significantly less activated HSCs and less fibrosis. These 
results revealed that c-JUN acts as a dual regulator in hepatic fibrosis, 
highlighting the importance of understanding how c-JUN functions in 
different liver cell types. Interestingly, hedgehog (Hh)-regulated transcription 
factor Gli2 expression was markedly increased in c-Jun-/- MEFs as compared 
to c-Jun+/+ MEFs. This correlates with previous studies showing a crucial role 
for Hh signaling in HSC activation and promotion of hepatic fibrosis. We 
therefore examined the Hh pathway activation in embryos and detected 
profoundly elevated Hh signaling in c-Jun-/- embryos compared to c-Jun+/+ 
embryos. Taken together, these data strongly suggest that the crosstalk 
between c-JUN and the Hh signaling pathway could be a possible mechanism 
of how c-JUN regulates hepatic fibrosis. 
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1.1 General introduction to eukaryotic gene expression regulation 
Eukaryotic organisms are constantly and simultaneously exposed to various 
kinds of physiological and environmental stimuli, such as nutrients, heat, 
radiation and mechanical stresses. These signals from outside the cells need to 
be transmitted all the way to the nucleus to cause gene expression changes to 
modify their behaviors accordingly (Figure 1) (Lodish, 2004 Chapter 15, 
Krauss, 2014 Chapter 1). This is a decision making process and therefore, is 
critical for normal life. Hence gene expression needs to be tightly regulated 
both temporally and spatially to ensure that the organisms can mount 
appropriate responses to specific stimuli. Deregulated gene expression can 
result in diseases and disorders (Lodish, 2004).  
Cells regulate gene expression (induce or inhibit specific gene product) in a 
complex way. Simplistically, it can be regulated at any step from chromatin 
level to transcription, to RNA transport or degradation, to translation or post-
translation (Krauss, 2014 Chapter 4). Transcriptional regulation controls the 
level and duration of mRNA synthesis and is usually influenced by regulatory 
DNA sequences (named promoters, enhancers and silencers) and sequence-
specific DNA-binding proteins (generally termed as transcription factors). 
There are additional proteins such as coactivators/repressors, chromatin 
remodeling factors etc., that also play crucial roles in transcriptional 
regulation. All these factors interplay and form a complex regulatory network 
to help or hinder the recruitment of RNA polymerase to the promoter, thus 







Figure 1. Integrating signals with gene expression 
Signals from outside the cells can be transmitted into the nucleus via (1) plasma 
membrane receptors via intracellular signaling molecules and/or (2) cytosolic nuclear 
receptors that move into the nucleus directly upon binding ligands. The signals 
converge to activate trancriptional regulatory proteins that eventually cause gene 
expression changes and cell fate decision. Figure adapted from Krauss, 2014  Figure 
1.8.  
 
Transcription factors can trans-activate (upregulate) or trans-repress 
(downregulate) gene expression in a context-dependent manner. Important 
transcription factors like p53 can control the expression of key proteins (e.g. 
p21, Puma and Noxa) to determine cell fate (e.g. cell cycle arrest, apoptosis 
and senescence) (Levine, 1997, Zuckerman et al., 2009). Therefore it is of 
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particular importance to understand how transcription factors and their 
responsive target genes work in facilitating the cells/organisms to 
accommodate to the environmental changes.  
1.2 AP-1 family of transcription factors 
Activator protein-1 (AP-1) is one of the earliest identified mammalian 
transcription factors. AP-1 was first identified as a 12-O-tetradecanoyl-
phorbol-13-acetate (TPA)-inducible transcription factor that could bind to the 
promoter/enhancer elements of several genes such as human metallothionein 
IIA, simian virus 40, collagenase and stromelysin to potentiate their 
transcription (Angel et al., 1991). In addition to TPA, AP-1 can be induced by 
a wide diversity of physiological and pathological signals including growth 
factors, neurotransmitters, genotoxic stresses, oncogenic proteins, 
inflammatory cytokines and chemokines, as well as bacterial and viral 
infections; and functions in almost all areas of eukaryotic cellular behavior, 
including cell proliferation and apoptosis, tissue development and 
regeneration, tumor initiation and progression (Shaulian et al., 2002, Eferl et 
al., 2003b, Zenz et al., 2006). 
1.2.1 AP-1 family components 
AP-1 is not a single protein, but consists of a dimeric complex of members 
from the Jun, Fos, ATF (activating transcription factor) and MAF 
(musculoaponeurotic fibrosarcoma) subfamily of proteins (Figure 2). Protein 
members from each subfamily are listed in Table 1 and among all the AP-1 
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members, Jun and Fos proteins are the prototypic components of the AP-1 
complex (Shaulian et al., 2002, Eferl et al., 2003b).  
  
 
Figure 2. The AP-1 transcription factor  
The AP-1 transcription factor is a dimer composed of members from the Jun, Fos, 
ATF and MAF subfamilies. Jun and Fos proteins are the prototypic components of 
the AP-1 complex (based on Protein Data Bank entry 1fos). AP-1 components 
dimerize through their leucine zipper domains and are able to recognize diverse 
DNA-binding sequences. The figure depicts crystal structure from c-JUN and c-FOS 
(62 amino acids each). Figure adapted from Eferl & Wagner, 2003 Figure 1a.  
 
Table 1. List of all the AP-1 family members 
AP-1 
Subfamily 





















Proteins constituting the AP-1 complex dimerize through their leucine zipper 
domains (Figure 2). Jun proteins can homo- and heterodimerize, whereas Fos 
proteins can only heterodimerize with other AP-1 proteins. AP-1 proteins, 
having the capabilities to form multiple combinations of homo- and 
heterodimers, are able to recognize diverse DNA-binding sequences which in 
turn regulate a broad spectrum of target gene expression (Karin et al., 1997, 
Shaulian et al., 2002, Eferl et al., 2003b). 
1.2.2 AP-1 dimer composition 
Is there any specific function of these different AP-1 dimers? Or do Jun-Jun, 
Jun-Fos and Jun-ATF classes of AP-1 dimers function redundantly? Many 
studies have suggested that different AP-1 dimers are regulated by different 
signaling pathways, interacting with different proteins and displaying different 
stabilities, DNA-binding specificities and trans-activating capacities (Hai et 
al., 1991, Chinenov et al., 2001, van Dam et al., 2001, Bakiri et al., 2002, 
Wisniewska et al., 2007, Walters et al., 2014).  
Firstly, different classes of AP-1 dimers can be activated by different specific 
stimulus. For example, growth factors or phorbol esters primarily stimulate the 
de novo synthesis of Jun-Fos by activating extracellular signal-regulated 
kinases (ERKs); while stresses like ultraviolet light (UV) predominantly 
enhance the activity of Jun-ATF via phosphorylation of e.g. c-JUN at serines 
63/73 and ATF2 at threonines 69/71 by Jun amino-terminal kinases (JNKs) 
(van Dam et al., 2001). 
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In addition, Jun-Jun and Jun-Fos dimers bind to the heptameric sequence 5‟-
TGA(C/G)TCA-3‟, known as TPA-response element (TRE) with high 
affinity; whereas Jun-ATF dimers bind preferentially to the octameric cyclic 
AMP-responsive element (CRE) 5‟-TGACGTCA-3‟ (Figure 3) (Karin et al., 




Figure 3. Examples of AP-1 dimer composition 
Jun-Fos and Jun-ATF are different AP-1 dimers that bind preferentially with different 
consensus sequences and regulate different sets of target genes. Figure adapted from 
van Dam & Castellazzi, 2001 Figure 1. 
 
Within Jun-Fos dimers, despite that all the Fos family proteins can form stable 
heterodimers with c-JUN, different dimers confer different transcriptional 
activity. Transcriptional activity of c-JUN on certain target genes was 
stimulated when heterodimerized with c-FOS but, on the contrary, it was 
suppressed when bound to FRA2 (Suzuki et al., 1991).  
In accordance, tethered AP-1 dimers have been generated by using a specially 
designed flexible polypeptide to join specific AP-1 components (e.g. c-
JUN~c-FOS, JUNB~c-FOS, JunD~c-FOS and c-JUN~FRA2) in order to 
study the function of individual AP-1 dimers (Bakiri et al., 2002). In addition, 
transgenic mice expressing individual forced AP-1 dimers have also been 
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generated for in vivo studies (Hasenfuss et al., 2014b). Interestingly, when 
expression of these forced AP-1 dimers was restricted to the liver parenchyme, 
all forced Jun~c-FOS dimers (c-JUN~c-FOS, JunB~c-FOS and JunD~c-FOS) 
strongly stimulated liver Peroxisome Proliferator-Activated Receptor γ 
(PPARγ) signaling (while c-JUN~c-Fos exhibited the strongest induction) and 
caused a lethal liver dysplasia phenotype. In contrast, forced c-JUN~FRA2 
dimer suppressed PPARγ signaling and could therefore protect the mice from 
high fat diet-induced nonalcoholic fatty liver disease (NAFLD) (Hasenfuss et 
al., 2014b). These data further provided in vivo evidence that different 
composition of the AP-1 dimers can lead to completely opposite physiological 
outcome. 
Hence, understanding AP-1 function and regulation requires careful 
investigation due to the broad combinatorial possibilities of AP-1 dimers. 
1.2.3 AP-1 abundance and activity 
The AP-1 abundance and activity can be regulated at multiple levels, 
including transcriptional, post-translational modification and interaction with 
ancillary proteins. The specific regulation at each level is delineated below. 
Firstly, AP-1 components are regulated at the transcriptional level. As AP-1 
controls both basal and inducible transcriptional activity, some AP-1 
components (often JUND, FRA1 and FRA2) are abundant under unstimulated 
condition for its basal activity, whereas the transcription of other AP-1 
components (like c-JUN and c-FOS) needs to be potentiated by stimuli. Hence 
the subunit composition of the AP-1 complexes would change with regard to 
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the relative proportions of different components present in the cells at a given 
time, which would in turn modulate AP-1 DNA-binding as well as target gene 
transcription (Wisdom, 1999). 
Secondly, AP-1 components are regulated at the protein level. In the case of c-
JUN, its amino-terminal (N-terminal) phosphorylation reduces its ubiquitin-
dependent degradation therefore increases its stability to a certain extent 
(Musti et al., 1997). However, carboxyl-terminal (C-terminal) region of c-
FOS is important for its degradation by c-JUN and multiple protein kinases 
(Tsurumi et al., 1995). 
Thirdly, both pre-existing and newly synthesized AP-1 components are 
modified at the post-translational level. Phosphorylation by protein kinases 
from the mitogen activated protein kinase (MAPK) family in modulating AP-1 
activities has been studied most extensively. Further details of this family of 
kinases are discussed in the next part. Additionally, other kinases such as 
casein kinase II (CkII), glycogen synthase kinase 3β (Gsk-3β) and ribosomal 
S6 kinase 2 (RSK2) have also been reported to phosphorylate Jun and Fos 
proteins thereby regulating their DNA-binding and transactivation potential 
(Eferl et al., 2003b). 
Lastly, other transcriptional regulators synergize or interfere with AP-1 
proteins and thereby regulate their activity. The DNA-binding potential of AP-
1 can be influenced by cofactors like Jun activation domain-binding protein 1 
(Jab1) (Zenz et al., 2006). Transactivation activity of AP-1 can be enhanced 
by interaction with transcriptional coactivators such as members of the CREB 
binding protein (CBP)/p300 family (Karin et al., 1997). In contrast, 
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glucocorticoid receptor (GR) and retinoic-acid receptor (RAR) are examples 
of ancillary proteins that can inhibit AP-1 activity (Angel et al., 1991, Eferl et 
al., 2003b).  
1.3 MAPK family of protein kinases 
The MAPKs are a group of evolutionarily conserved proline-directed 
serine/threonine protein kinases that are activated by dual phosphorylation on 
threonine and tyrosine residues in response to a wide range of extracellular 
stumuli. The MAPK pathway is a very important intracellular signaling 
pathway that serves to receive, amplify and integrate signals from 
extracellular environment to the transcriptional machinery in the nucleus, 
which ultimately results in a diverse array of cellular and physiological 
responses such as proliferation, apoptosis, differentiation and inflammation 
(Whitmarsh et al., 1996, Karin, 1998, Chang et al., 2001). 
1.3.1 MAPK signaling cascade  
The canonical MAPK signaling (Figure 4) is organized in a phosphorelay 
system composed of three sequentially activated protein kinases: MAPK, 
MAPK kinase (MAPKK, MEK or MKK) and MAPK kinase kinase 
(MAPKKK or MEKK). Specific signals trigger the activation of MAPKKKs, 
which in turn phosphorylate and activate MAPKKs; MAPKKs thereafter 
phosphorylate and activate MAPKs which then translocate into cell nucleus 
and phosphorylate a variety of transcription factors on specific sites to 
regulate their transcriptional activity (Karin, 1998, Chang et al., 2001, 





Figure 4. Canonical MAPK signaling cascade 
MAPK signaling is activated by a wide range of extracellular stimuli and organized 
in a phosphorelay system. Conventionally, there are three major groups of MAPKs: 
ERKs (ERK1/2), JNKs (JNK1/2/3) and p38 proteins (p38α/β/γ/δ). Figures adapted 
from Cargnello & Roux, 2011 Figure 2. 
 
In mammals, there are three major groups of MAPKs that have been 
identified: the ERKs (ERK1/2), JNKs (JNK1/2/3) and p38 proteins 
(p38α/β/γ/δ) (Figure 4) (Karin, 1998, Chang et al., 2001, Cargnello et al., 
2011). Individual MAPKs can be activated and signal independently from 
each other. The ERKs are more efficiently activated by signals like growth 
factors and phorbol esters, which transmit through receptors containing 
intrinsic tyrosine kinase domains or receptors that interact with cytoplasmic 
tyrosine kinases, thus preferentially regulate cellular growth, differentiation 
and transformation (Boulton et al., 1990). The JNKs and p38 MAPKs are 
more potently activated by environmental stresses and proinflammatory 
cytokines and function mainly in inflammation and apoptosis (Bogoyevitch et 
al., 2010, Cuadrado et al., 2010). 
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1.3.2 The regulation of AP-1 by MAPKs 
One important nuclear target of these MAPKs is AP-1. MAPKs regulate AP-1 
activity by both increasing the abundance of AP-1 components through 
upregulation of transcription and enhancing the AP-1 activity via 
phosphorylation (Karin, 1995, Whitmarsh et al., 1996, Karin et al., 1997). 
ERKs, JNKs and p38 MAPKs all have been demonstrated to increase c-Fos 
transcription through phosphorylation and activation of members from ternary 
complex factor (TCF) DNA-binding proteins. TCF together with a dimeric 
serum response factor (SRF) form a ternary complex that can bind to c-Fos 
promoter and activate its transcription upon various stimuli (Whitmarsh et al., 
1996, Shaulian et al., 2002). Moreover, JNKs have been shown to increase c-
Jun transcription through phosphorylation and activation of c-JUN and ATF2. 
Since c-Jun promoter is constitutively occupied by c-JUN-ATF2 heterodimer, 
phosphorylation of c-JUN and ATF2 by JNKs increases their transcriptional 
activity, thereby leading to an increase in c-Jun transcription (Whitmarsh et 
al., 1996, Mechta-Grigoriou et al., 2001). 
Phosphorylation of AP-1 components by MAPKs has been extensively 
documented. ERKs have been reported to directly phosphorylate FRA1 and 
FRA2; JNKs can phosphorylate c-JUN and ATF2; p38 kinases can also 
phosphorylate ATF2, all of which contributes to enhanced AP-1 activity  
(Whitmarsh et al., 1996, Karin et al., 1997, Shaulian et al., 2002). 
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1.3.3 The JNK/Jun signal transduction pathway 
The JNK protein kinases were first identified through their ability to 
phosphorylate c-JUN on its N-terminal stimulatory sites. The JNKs are 
encoded by three genes: jnk1, jnk2 and jnk3 (Figure 5). The jnk1 and jnk2 
genes are ubiquitously expressed whereas the jnk3 expression is limited to 
brain, heart and testis. These three genes are alternatively spliced to generate 




Figure 5. JNK isoforms 
The JNKs are encoded by three genes (jnk1, jnk2 and jnk3) that are alternatively 
spliced to generate ten JNK isoforms. Figure adapted from Manning & Davis, 2003 
Figure 1. 
 
JNKs can be activated by diverse stimuli, such as cytokines (tumor necrosis 
factor [TNF], interleukin [IL]-1, transforming growth factor [TGF]-β, platelet-
derived growth factor [PDGF], epidermal growth factor [EGF]), pathogens 
(lipopolysaccharide [LPS]), reactive oxygen species (ROS), stresses (UV, 
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ionizing radiation [IR], hypoxia, endoplasmic reticulum stress), etc. (Seki et 
al., 2012). Most of the above mentioned stimuli activate JNKs which in turn 
activate c-JUN. c-JUN then dimerizes with other AP-1 members and regulates 
downstream gene expression. 
JNKs can phosphorylate c-JUN and ATF2 (Shaulian et al., 2002). c-JUN is 
expressed at a relatively low level under normal unstimulated condition. JNKs 
phosphorylate c-JUN efficiently to thereby enhance its transcriptional activity. 
Phosphorylation can occur at serines 63/73 and/or threonines 91/93 
(Vinciguerra et al., 2008, Reddy et al., 2013). Unlike c-JUN, ATF2 is 
constitutively expressed. ATF2 is also rapidly phosphorylated by JNKs 
following stimulation and can dimerize with c-JUN to regulate certain AP-1 
target genes (Gupta et al., 1995).  
Interestingly, JNKs can also phosphorylate JunD by a slightly different 
process. JNK requires a docking site in its substrate to tether and 
phosphorylate it (Karin et al., 1997). JunD lacks the JNK docking site but 
contains JNK phosphoacceptor sites. JUNB, on the other hand, possesses the 
JNK docking site but does not have proper JNK phosphoacceptor sites. As a 
result, JUNB is not phosphorylated by JNKs whereas JunD can be 
phosphorylated by JNKs only when it forms heterodimers with c-JUN or 
JUNB which have the effective JNK docking sites. 
1.4 Basic Introduction to c-JUN 
The mouse and human c-Jun share high degree of identity. Human c-jun gene 
is located on chromosome 1 and murine c-jun gene is on chromosome 4. 
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Cloning of the c-Jun gene revealed that it has no introns (Vogt, 2001), thus, c-
Jun has no isoforms and no post-transcriptional regulation. 
1.4.1 The discovery of c-JUN 
c-Jun was originally discovered as a cellular counterpart of v-jun, an oncogene 
isolated from the genome of the avian sarcoma virus 17 (ASV 17) (Maki et 
al., 1987). Two seminal findings placed c-JUN as the core component of the 
AP-1 complex. (1) Structural analysis revealed a homology between the C-
terminal region of c-JUN and the DNA-binding domain of a yeast 
transcription factor GCN4. As GCN4 was already known to bind to AP-1 site, 
this led to the discovery that c-JUN is part of the AP-1 complex (Bohmann et 
al., 1987, Vogt et al., 1987, Angel et al., 1988a). (2) c-JUN was also 
recognized as a Fos-associated protein that could cooperate with Fos to 
stimulate gene expression. With more identity and functional tests, c-JUN was 
quickly determined as the major component of the AP-1 complex (Rauscher et 
al., 1988, Sassone-Corsi et al., 1988). 
1.4.2 The structure of c-JUN 
The simplified structure of c-JUN is illustrated in Figure 6. c-JUN protein, like 
all other AP-1 family members, belongs to the basic region-leucine zipper 
(bZIP) group of DNA-binding transcription factors (Shaulian et al., 2002, 





Figure 6. The basic structure of the murine c-JUN 
c-JUN possesses a transactivation domain that covers the majority of its N-terminus 
however lacking defining structural borders. c-JUN also contains a DNA-binding 
domain (yellow) and a dimerization domain (blue) at its C-terminus. A delta domain 
(pink) locates near its N-terminus, functions as the JNK docking site. JNKs bind and 
phosphorylate c-JUN at mainly serines 63 and 73; this phosphorylation event is 
named as c-JUN amino-terminal phosphorylation (JNP). 
 
c-JUN can form homo- or heterodimers with various bZIP proteins through its 
C-terminal dimerization domain. This dimerization domain contains five 
heptad repeats of the leucine residues forming an amphipathic helix that is 
referred as the leucine zipper motif and is responsible for protein-protein 
interaction (Vogt, 2001).  
A highly charged basic region located immediately N-terminal to the leucine 
zipper motif is the DNA-binding domain of c-JUN, which makes direct 
contact with DNA. Importantly, dimerizations between the AP-1 components 
is a prerequisite for their DNA-binding (Vogt, 2001). 
There is a region of 27 amino acids, termed the delta domain, near the N-
terminus of c-JUN that is not present in v-Jun. This domain was found to be 
required for c-JUN poly-ubiquitination and subsequent proteolysis and is 
hence involved in regulating c-JUN turnover. v-Jun therefore could escape 
poly-ubiquitination and is more stable than c-JUN (Treier et al., 1994). 
Moreover, as mentioned before, the delta domain also serves as the docking 
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site for JNKs to phosphorylate c-JUN. The integrity of this docking site is 
essential for c-JUN phosphorylation by JNKs. v-Jun therefore is not 
phosphorylated by JNKs (Adler et al., 1992, Hibi et al., 1993). 
The transactivation domain of c-JUN lacks defining structural features. 
Numerous independent studies on various c-JUN deletion mutants have 
revealed that the majority of its N-terminal region constitutes its 
transactivation domain (Vogt, 2001). The transactivation domain has been 
shown to be important in most c-JUN functions such as transcriptional 
activation, cell proliferation, cell death and transformation (Shaulian et al., 
2001, Shaulian et al., 2002, Eferl et al., 2003b). 
1.4.3 The regulation of c-JUN  
The regulation of c-JUN generally occurs at transcriptional and post-
translational levels. 
The c-Jun gene is transcribed at low levels prior to stimulation. Nevertheless it 
is an immediate early gene whose transcription is rapidly induced following 
stimulation (Karin et al., 1997). The c-Jun promoter region is highly 
conserved between mouse, rat and human (Mechta-Grigoriou et al., 2001). c-
JUN can positively autoregulate its own transcription through the interaction 
with two TRE-like sequences present within its promoter (Angel et al., 
1988b). 
The activity of c-JUN is primarily regulated by phosphorylation. Structural 
analysis revealed that c-JUN has many potential phosphorylation sites, such as 
serines 63, 73, 243, threonines 91, 93, 239 and tyrosine 170. Most of these 
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residues and the associated kinases have been examined (Barila et al., 2000, 
Morton et al., 2003, Gao et al., 2006, Zhu et al., 2006, Vinciguerra et al., 
2008, Xie et al., 2010, Reddy et al., 2013). Among all the phosphorylation 
sites, serines 63 and 73 have been studied most intensively as they are 
recognized as the most crucial sites in regulating c-JUN stability and activity 
(Shaulian et al., 2002, Eferl et al., 2003b). Moreover, phosphorylation of c-
JUN at a cluster of sites located just upstream of its basic region (DNA-
binding domain) was found to inhibit c-JUN binding to DNA. 
Dephosphorylation at one or more of these sites could therefore increase c-
JUN DNA-binding and transactivation activity (Boyle et al., 1991). 
Poly-ubiquitination is another post-translational modification that regulates c-
JUN protein turnover. Several E3 ubiquitin ligases have been identified to 
target c-JUN for proteasomal degradation, such as Itch and COP1 (Gao et al., 
2004, Wertz et al., 2004). Phosphorylation of c-JUN at multiple sites within 
its transactivation domain by MAPKs generally reduces its poly-ubiquitination 
and stabilizes c-JUN (Musti et al., 1997). Interestingly, Fbw7, the substrate 
recognition component of an SCF-type E3 ubiquitin ligase that is highly 
expressed in the nervous system, specifically targets the N-terminal 
phosphorylated c-JUN and facilitates its degradation, thus antagonizing 
excessive c-JUN activity in neurons (Nateri et al., 2004). 
1.4.4 c-JUN amino-terminal phosphorylation (JNP) 
To date, JNK is still considered as the primary regulator of c-JUN and its 
phosphorylation on serines 63/73 within c-JUN transactivation domain is 
believed to be the most crucial event in regulating c-JUN activity. This 
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phosphorylation event is thus termed as c-JUN amino-terminal 
phosphorylation (JNP) (Figure 6) (Behrens et al., 1999).  
Collectively, JNP is found to (1) regulate the ubiquitin-mediated degradation 
of c-JUN to thus increase c-JUN abundance; (2) increase c-JUN DNA 
binding; (3) increase the ability of c-JUN to interact with coactivators like 
CBP/p300 thus enhance c-JUN transactivation potential (Karin et al., 1997, 
Mechta-Grigoriou et al., 2001).  
1.5 c-JUN and JNP in cell life and death 
Initial studies using cells and mice deficient for c-JUN or JNP have provided 
substantial functional insights in their functions in regulating cell proliferation, 
oncogenic transformation and apoptosis. 
1.5.1 Cell cycle progression and proliferation 
c-JUN is a positive regulator of cell proliferation supported by multiple lines 
of evidence and will be briefly described. (1) c-JUN depletion using antisense 
RNA in erythroleukemia cells inhibited cell proliferation (Smith et al., 1992). 
(2) c-JUN-deficient primary mouse embryonic fibroblasts (MEFs) exhibited 
severe proliferation defects with almost no growth rate in culture and quickly 
entered premature senescence (Johnson et al., 1993, Schreiber et al., 1999). 
(3) Similar phenotype was also observed in immortalized c-Jun-/- MEFs and 
re-introduction of c-JUN could rescue this phenotype and increase 
proliferation (Schreiber et al., 1999). (4) c-JUN-deficient primary 
keratinocytes (Li et al., 2003, Zenz et al., 2003) and fetal hepatoblasts (Eferl 
et al., 1999) also displayed markedly reduced proliferation in vitro. (5) 
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Moreover, loss of c-JUN significantly impaired postnatal hepatocyte 
proliferation in vivo as assessed by Bromodeoxyuridine (BrdU) labeling 
(Behrens et al., 2002). c-JUN could, in addition, affect cell cycle re-entry. (6) 
Microinjection of c-JUN antibody into quiescent mouse fibroblasts greatly 
inhibited DNA synthesis and prevented cell cycle re-entry following serum 
stimulation (Kovary et al., 1991). (7) While wild type fibroblasts underwent a 
transient cell cycle arrest after exposure to UV, c-Jun-/- cells exhibited 
prolonged growth arrest and failed to resume proliferation (Shaulian et al., 
2000). (8) Quiescent adult hepatocytes lacking c-JUN also failed to re-enter 
cell cycle after partial hepatectomy (PH) thus resulting in impaired liver 
regeneration (Behrens et al., 2002).  
Genetic and biochemical analysis have revealed that the regulation of cell 
cycle progression and cell proliferation by c-JUN is through its ability to 
downregulate p53. c-JUN has been shown to bind and suppress p53 
transcription, thereby indirectly downregulating the p53 target gene p21, an 
inhibitor of cyclin-dependent kinase (CDK). Hence absence of c-JUN results 
in elevated levels of both p53 and p21, subsequently low CDK activity and 
therefore retards cell cycle progression. Importantly, deletion of p53 could 
completely rescue the proliferation defect of c-Jun-/- cells (Schreiber et al., 
1999). Similarly, c-JUN can also repress UV-induced p53-mediated p21 
induction. Thus absence of c-JUN leads to prolonged activation of p53 and 
p21 following UV stimulation, leading to inefficient cell cycle re-entry 
(Shaulian et al., 2000). Furthermore, c-JUN has also been proposed to control 
cell cycle progression by directly regulating cyclin D1 expression (Bakiri et 
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al., 2000), suggesting that c-JUN can regulate multiple cell proliferation 
pathways. 
On the other hand, JNP has been shown to affect cell proliferation only 
partially. Cells harboring mutant c-Jun alleles, where the JNK 
phosphoacceptor sites serines 63 and 73 were mutated to alanines (c-JunAA/AA), 
exhibited a partial proliferation defect. Proliferation analysis by counting the 
cumulative cell numbers demonstrated that the proliferation rate of primary c-
JunAA/AA MEFs and keratinocytes were intermediate between c-Jun+/+ and c-
Jun-/- cells (Behrens et al., 1999, Li et al., 2003).  
1.5.2 Cellular oncogenic transformation  
Since discovery, c-Jun has been recognized as the cellular homologue of a 
retroviral oncogene that can transform chicken cells (Maki et al., 1987). 
Moreover, c-JUN activity can be augmented by various tumor promoters and 
activated oncoproteins (Vogt, 2001, Eferl et al., 2003b). Detailed 
investigations have then established its role in oncogenic transformation. 
Overexpression of c-Jun alone could transform immortalized rodent 
fibroblasts and the transformed cells could form tumors in nude mice, 
emphasizing its ability in malignant transformation (Schutte et al., 1989). 
However, overexpression of c-Jun alone was not sufficient to transform 
primary rodent embryo cells. Transformation of primary cells, instead 
required c-Jun in combination with other activated oncogene such as H-ras 
that could then give rise to tumors in nude mice (Schutte et al., 1989, Vandel 
et al., 1996). Importantly, c-JUN is required for Ras-mediated oncogenesis, as 
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c-Jun-/- cells were refractory to Ras-induced transformation and were unable 
to form tumors in nude mice (Johnson et al., 1996a). In addition, c-JUN also 
efficiently cooperates with c-FOS to enhance osteosarcoma formation caused 
by c-Fos overexpression (Wang et al., 1995). 
JNP has been demonstrated to contribute partially to c-JUN's ability to 
cooperate with other oncoproteins. Although immortalized c-Jun+/+ and c-
JunAA/AA fibroblasts exhibited morphologically indistinguishable oncoprotein-
induced in vitro transformation, the ability of the transformed cells to form 
tumors in nude mice varied dramatically. Absence of JNP considerably 
reduced v-Ras-induced tumor volume and significantly delayed v-Fos-induced 
tumor initiation (Behrens et al., 2000). 
1.5.3 Programmed cell death 
The role of c-JUN in apoptosis is cell type dependent. Several cell types have 
been examined to evaluate the effect of c-JUN on apoptosis, including 
lymphoid cells, neuronal cells, fibroblasts and hepatocytes. c-JUN was 
observed to promote apoptosis in some cell types and prevent apoptosis in 
others (Mechta-Grigoriou et al., 2001, Shaulian et al., 2001, Shaulian et al., 
2002). 
(1) Inhibition of c-JUN by antisense oligonucleotides protected growth factor 
deprivation-induced apoptosis in IL-6 and IL-2 dependent cell lines (Colotta et 
al., 1992). (2) Inhibition of c-JUN by a neutralizing antibody or targeted 
deletion of c-JUN by Cre recombinase reduced apoptosis of primary 
sympathetic neuron cultures from nerve growth factor (NGF) withdrawal 
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(Estus et al., 1994, Palmada et al., 2002). (3) c-JUN-deficient fibroblasts were 
resistant to apoptosis triggered by genotoxic stresses such as UV (Shaulian et 
al., 2000) and alkylating agents (Kolbus et al., 2000). (4) Moreover, 
overexpression of c-JUN alone was sufficient to trigger apoptosis in 
sympathetic neurons (Ham et al., 1995) and fibroblasts (Bossy-Wetzel et al., 
1997). All these data demonstrate the pro-apoptotic effect of c-JUN. 
In contrast to the pro-apoptotic function during survival factor withdrawal or 
genotoxic stresses as mentioned above, c-JUN also exerts a protective role 
particularly in liver cells during embryonic development. c-JUN-deficient 
embryo livers exhibited massive apoptosis in hepatoblasts and hematopoietic 
cells (Hilberg et al., 1993, Eferl et al., 1999). 
JNP is important for c-JUN-induced apoptosis. The involvement of JNP in 
apoptosis has been demonstrated in fibroblasts, lymphocytes and neuronal 
cells. N-terminal truncated (dominant negative) c-JUN mutants which are 
disabled for JNP but still possess the dimerization and DNA-binding ability 
have been utilized to assess the effect of JNP on apoptosis. (1) Expression of 
dominant negative c-JUN mutant greatly inhibited apoptosis in human 
monoblastic leukemia cells upon various stresses including IR, hydrogen 
peroxide, UV, heat shock and TNF-α (Verheij et al., 1996). (2) Expression of 
different forms of dominant negative c-JUN mutants significantly reduced 
apoptosis induced by NGF withdrawal in both sympathetic neurons and PC12 
cells respectively (Ham et al., 1995, Xia et al., 1995). (3) The N-terminal 
pseudo-phosphorylated c-JUN mutant induced cerebellar granule neuron 
(CGN) cell death and the N-terminal nonphosphorylatable c-JUN mutant 
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blocked CGN cell death (Watson et al., 1998). (4) Primary sympathetic 
neurons isolated from c-JunAA/AA mice significantly delayed trophic factor 
deprivation-induced apoptosis (Besirli et al., 2005). (5) c-JunAA/AA mice-
derived primary cortical/hippocampal neurons were resistant to kainic acid-
induced cytotoxicity and therefore the mice were also protected from kainic 
acid-induced epileptic seizures (Behrens et al., 1999). 
1.6 c-JUN and JNP in development 
The emergence of genetic modification techniques allows distinct genes to be 
inactivated, mutated or ectopically expressed in mice in order to study their 
physiological functions. Mice harboring various types of genetically modified 
c-Jun have revealed many physiological and pathological functions of c-JUN 
and JNP. 
c-JUN is expressed almost ubiquitously during and is essential for embryonic 
development. Homozygous c-Jun knockout mice (c-Jun-/-) are embryonically 
lethal and die at mid-gestation between embryonic day E12.5 and E14.5 days 
(Hilberg et al., 1993, Johnson et al., 1993). The major organs affected by 
genetic c-Jun ablation are the liver and the heart (Hilberg et al., 1993, Eferl et 
al., 1999). 
Surprisingly, JNP is dispensable for embryonic development. Homozygous c-
Jun knock-in mice carrying mutant alleles of c-Jun, where the two most 
important phosphoacceptor sites serines 63 and 73 mutated to alanines (c-
JunAA/AA) to prevent the their phosphorylation by JNKs, are viable and fertile 
with no major defects (Behrens et al., 1999). 
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c-JUN conditional knockout (c-Jun gene flanked by two loxP sites, c-Junf/f) 
mice (Behrens et al., 2002) were generated to bypass the embryonic lethality 
caused by absence of c-Jun. Based on the Cre-loxP recombination system 
(Orban et al., 1992), c-JUN can be somatically removed at various stage of 
life and/or in different cell types/organs thus enabling further investigation on 
loss-of-function phenotypes. 
1.6.1 Liver development 
One of the most important organs affected by c-JUN deletion during 
embryonic development is the liver. Detailed histological analyses revealed 
that the morphological abnormalities of c-Jun-/- livers emerged from E13.0; 
characterized by increased number of apoptotic and necrotic hepatoblasts and 
hematopoietic cells. Although the exact cause of the lethality of c-Jun null 
fetuses has not been determined yet, their liver defect was suggested to be the 
main reason (Hilberg et al., 1993, Eferl et al., 1999).  
Another key evidence delineating the significance of c-JUN in liver 
development is from the analysis of the chimeric mice generated from c-Jun-/- 
embryonic stem (ES) cells. Although c-Jun-/- ES cells were able to 
differentiate into all organs (including liver), c-Jun-/- ES cell derivatives were 
progressively lost in chimeric mouse livers after birth, presumably by 
imbalanced c-Jun+/+ and c-Jun-/- hepatic cell turnover in the adult chimeric 
mice (Hilberg et al., 1993, Eferl et al., 1999).  
Rodent liver continues to develop postnatally characterized by rapid 
hepatocyte proliferation and several fold increase of liver mass within the first 
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few weeks after birth (Behrens et al., 2002). Function of c-JUN in postnatal 
liver development has also been analyzed using mice with perinatal (around 
E17.5) hepatocyte-specific inactivation of c-Jun (c-Junf/f;Alfp-Cre; Alfp: 
albumin promoter and alpha feto-protein enhancers). These mice are viable 
with reduced liver and body weight compare to wild type mice and do not 
display any overt impaired liver functions. However the postnatal hepatocyte 
proliferation was significantly reduced as assessed by BrdU incorporation of 
S-phase hepatocytes, indicating that c-JUN is required for early postnatal 
hepatocyte proliferation (Behrens et al., 2002). 
1.6.2 Heart development 
Besides the liver defect, all c-JUN null fetuses analyzed also showed defect in 
heart development. Histological analysis of E12.5 embryos revealed a 
malformation of the heart outflow tract in all c-Jun-/- fetuses, which resemble 
the congenital human disease of a persistent truncus arteriosus, indicating a 
role of c-JUN in embryonic heart development (Eferl et al., 1999). 
1.6.3 Skin development 
The mammalian skin consists of two primary layers, the epidermis and the 
dermis, which are separated by the basal lamina. From embryonic 
development till birth, c-JUN expression was found to be restricted to the 
epidermis layer in mice (Angel et al., 2001). Normal development of 
epidermis requires proper keratinocytes proliferation, differentiation and 
migration. Two separate studies using Cre recombinase driven by different 
keratinocyte-specific promoters (Keratin 5 [K5] and Keratin 14 [K14]) to 
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conditionally ablate c-JUN in epidermis both revealed interesting functions of 
c-JUN in skin development (Li et al., 2003, Zenz et al., 2003). 
Mice with epidermis-specific inactivation of c-JUN (c-Junf/f;K5-Cre and c-
Junf/f;K14-Cre) developed normal skin but both showed distinctively impaired 
eyelid development. The eyelids of wild type mice remain fused until 
approximately 10 days after birth. However, the mutant mice are born with 
open eyes and this phenotype is readily detectable before birth. The eyelids of 
these mutant mice fail to fuse during ontogenesis most likely due to 
insufficient EGF receptor (EGFR) expression in the keratinocytes at the 
leading edges of the developing eyelids, which results in defective eyelid 
epithelial cell migration. In addition, keratinocytes lacking c-JUN also 
exhibited defect in actin microfilaments distribution and organization. This 
cytoskeletal defect may be involved in the failure of mutant epidermis to 
spread forward over the developing cornea  (Li et al., 2003, Zenz et al., 2003).  
1.7 c-JUN and JNP in tumorigenesis 
c-JUN and JNK activation have been associated in many human cancers 
(Wang et al., 2000, Liu et al., 2002, Papachristou et al., 2003). Manipulation 
of c-JUN and JNP in various mouse cancer models have provided some 
molecular explanations of how c-JUN and JNP contribute to tumorigenesis. 
1.7.1 Skin cancer 
The skin tumor prone K5-SOS-F transgenic mice, which express a dominant 
form of the guanine nucleotide exchange factor Son of Sevenless (SOS) in the 
basal keratinocytes develop skin papillomas with 100% penetrance (Sibilia et 
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al., 2000) and were used to investigate the role of c-JUN in skin 
carcinogenesis. 
K5-SOS-F mice with conditional c-Jun deletion in keratinocytes exhibited 
significantly confined and reduced number of proliferating keratinocytes and 
approximately 50% decreased tumor volume compared to the control mice, 
albeit their tumor numbers, apoptotic index, histological appearance and 
cellular composition were comparable to the control mice. Moreover, c-JUN 
was found to transcriptionally regulate EGFR expression. Thus the reduced 
expression of EGFR observed in tumors lacking c-JUN has been attributed as 
the main reason of reduced tumor growth. Hence, c-JUN was suggested to 
regulate skin tumor development through its modulation of EGFR signaling 
(Zenz et al., 2003). 
K5-SOS-F mice harboring the c-JunAA/AA mutant (to prevent JNP) also 
exhibited significantly reduced tumor sizes compared to the control mice at 
early stage of papilloma progression. However this protection was gradually 
lost with increasing age. Therefore, inactivating JNP resulted in delayed skin 
tumor formation induced by the hSOS-F transgene instead of abolishing it 
(Behrens et al., 2000). 
1.7.2 Intestinal cancer 
Adenomatous polyposis coli (APC) is a tumor suppressor and a key regulator 
of intestinal neoplasia. Humans carrying germline mutations in the Apc gene 
are at risk of developing multiple intestinal adenomas that can progress to 
cancer (Moser et al., 1993). Mice heterozygous for a nonsense mutation at 
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codon 850 of the Apc gene (ApcMin/+) (Moser et al., 1993) were used to 
investigate the involvement of c-JUN in intestinal cancer development. 
Genetic abrogation of JNP in the ApcMin/+ mice (ApcMin/+;c-JunAA/AA) 
significantly reduced their tumor numbers and sizes and prolonged their 
lifespan. The average lifespan of ApcMin/+;c-Jun+/+ and ApcMin/+;c-JunAA/AA 
mice were 15.7 versus 23.1 weeks respectively. Moreover, genetic abrogation 
of c-JUN showed a more pronounced effect. ApcMin/+ mice with conditional c-
Jun deletion in gut did not display any clinical sign of cancer development 
even at the age of 9 months. Collectively, these indicate that inactivation of 
JNP delays but inactivation of c-JUN protects ApcMin/+ mice from intestinal 
cancer development (Nateri et al., 2005).  
The mechanism of which c-JUN promotes intestinal tumorigenesis is through 
its JNP-dependent interactions with TCF4 and β-catenin, forming a ternary 
complex to regulate certain target gene transcription such as c-Jun and Cd44 
(Nateri et al., 2005).  
1.7.3 Liver cancer 
This will be discussed in section 1.8.4. 
1.8 c-JUN and JNP in liver pathology 
While c-JUN is essential in the fetal liver development, it appears to be 
dispensable for basic liver functions in the adult mice. In vivo studies 
comparing mice with c-JUN deletion in the adult livers to wild type mice 
revealed no overt differences at the morphological level as well as at the 
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biochemical (serum lipids and enzymes) level (Behrens et al., 2002). 
Nevertheless, JNK/c-JUN signaling is active and is a major player in many 
liver pathogenesis of various etiologies such as TNF-α, ischemia/reperfusion, 
acetaminophen and high fat diet (Seki et al., 2012). Studies analyzing mice 
with targeted disruption of c-JUN in the adult livers under various kinds of 
liver pathological conditions have uncovered many crucial roles of c-JUN in 
liver pathology and will be further discussed. 
1.8.1 Liver as an organ  
Liver is a vital organ and its functions include storing glycogen, vitamins and 
iron etc. to provide energy to the body, removal of toxic waste and drugs from 
the blood, helping to digest food and absorb nutrients and much more (Kuntz 
et al., 2008). Due to the fact that it is playing such an important role, strong 






Figure 7. Hepatic cell types and sinusoid 
Liver contains many different cell types, including hepatocyte (epithelial 
parenchymal cell), sinusoidal endothelial cell, Kupffer cell (resident macrophage) and 
hepatic stellate cell (HSC). Hepatic sinusoid is a type of capillary blood vessel lined 
with fenestrated sinusoidal endothelial cells and serves as the location for 
microcirculation. Figure adapted from Bataller & Brenner, 2005 Figure 1. 
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Liver is made up of a plethora of different cell types including hepatocyte, 
sinusoidal endothelial cell, Kupffer cell and hepatic stellate cell (HSC) (Figure 
7). Hepatocytes are the main parenchymal cells, making up 70-85% of the 
liver mass, separated from the liver sinusoids by the perisinusoidal space 
(Berry et al., 2000). They are cuboidal in shape and have distinctly round 
nuclei (Coleman et al., 2009). Sinusoidal endothelial cells are a type of non-
parenchymal cells that line to form sinusoid, which is the liver capillary. 
While they separate hepatocytes from sinusoidal blood, one of its role is 
hepatic microcirculation (Hernandez-Gea et al., 2011). Kupffer cells are the 
largest population of macrophages that are reside within the liver sinusoid 
(Klein et al., 2007). HSCs are vitamin A-storing cells residing in the 
perisinusoidal space, between the hepatocytes and the sinusoidal endothelial 
cells (Bataller et al., 2005).  
1.8.2 Liver regeneration 
Adult liver has a unique regenerative capability to reconstitute functional liver 
parenchyma within a short period of time after a substantial loss of liver mass. 
This regenerative process is mainly achieved by the rapid replication of the 
remaining hepatocytes. Adult hepatocytes, albeit quiescent and highly 
differentiated, have the ability to re-enter the cell cycle to grow, divide and 
ultimately restore the original liver mass within a few days (Fausto, 2000, 
Behrens et al., 2002).  
The impact of c-JUN on liver regeneration has been examined by 70% PH in 
adult mice with conditional inactivation of c-JUN in (1) hepatocytes (c-
Junf/f;Alfp-Cretg) and (2) hepatocytes and hematopoietic cells (c-Junf/f;Mx-
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Cretg). Both mutant mice exhibited severely impaired liver regeneration and 
approximately 50% mortality within 3 days after surgery, whereas wild type 
mice showed normal regeneration with 100% survival. The proliferating 
hepatocytes were severely reduced in mutant livers, indicating that c-JUN is 
required for mature hepatocytes to re-enter cell cycle and proliferate to 
reconstitute liver parenchyma after PH surgery (Behrens et al., 2002, Stepniak 
et al., 2006). Interestingly, this liver regeneration defect of the c-JUN mutant 
mice can be completely rescued in a p53 or p21-negative genetic background; 
hepatocyte proliferation after PH was fully restored in the double mutant mice 
(Stepniak et al., 2006). 
Although both c-JUN and JNP were strongly induced by PH in wild type 
mice, c-JunAA/AA mice, nevertheless, exhibited normal liver regeneration and 
no mortality after PH, indicating that JNP is not required for c-JUN function 
in hepatocyte proliferation (Behrens et al., 2002). 
1.8.3 Inflammatory liver diseases 
Inflammatory liver diseases are usually caused by hepatoviral infection and/or 
unhealthy diet. NAFLD is a common type of inflammatory liver disease and 
manifests as a metabolic syndrome as it is commonly associated with insulin 
resistance and obesity (Loomba et al., 2013). NAFLD ranges from simple 
steatosis to steatohepatitis. It is characterized by excessive lipid accumulation 
in hepatocytes as well as increased circulating free fatty acids which promote 
the production of proinflammatory cytokines such as TNF-α and endoplasmic 
reticulum stress. These in turn lead to hepatocellular injury and thus may 
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progress to more severe liver diseases such as cirrhosis and hepatocellular 
carcinoma (HCC) (Asrih et al., 2015). 
c-JUN has been found to be strongly expressed in the livers of patients with 
acute hepatitis (Hasselblatt et al., 2007) as well as with various degrees of 
NAFLD (Dorn et al., 2014). Detailed mouse model and biochemical studies 
have revealed a significant protective role of activated c-JUN in several types 
of liver injury and inflammation. 
In a hepatitis model, Concanavalin A (Con A) was used to induce liver injury 
through T cell activation, as well as expressing and releasing of TNF-α, 
thereby promoting hepatocyte death. With c-JUN deletion in (1) hepatocytes 
(c-Junf/f;Alfp-Cretg) and (2) hepatocytes and hematopoietic cells (c-Junf/f;Mx-
Cretg), Con A injection led to markedly increased mortality in both mutant 
mice as compared to wild type mice. The protection of hepatocyte death by c-
JUN was found to depend on its positive regulation of inducible nitric oxide 
synthase (nos2) gene and subsequent production of hepatoprotective nitric 
oxide (Hasselblatt et al., 2007).  In a endoplasmic reticulum stress model, 
thapsigargin and tunicamycin were used to induce endoplasmic reticulum 
stress followed by activation of the unfolded protein response. This can trigger 
cell death if the endoplasmic reticulum stress is not resolved. Hepatocytes 
lacking c-JUN (c-Junf/f;Alfp-Cretg) exhibited exacerbated and sustained 
endoplasmic reticulum stress characterized by massive cytoplasmic 
vacuolization and profound endoplasmic reticulum distension, therefore 
increased ballooning (death) compared to wild type hepatocytes. Interestingly, 
c-JUN-promoted hepatocyte survival during endoplasmic reticulum stress is 
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probably linked with autophagy as c-Jun-/- hepatocytes showed defects in 
autophagosome formation upon thapsigargin treatment  (Fuest et al., 2012). 
1.8.4 Liver carcinogenesis 
HCC is the most common type of primary liver cancer and the third leading 
cause of cancer-related death in the world. The main risk factors for HCC 
include hepatitis viral infection, aflatoxin B-contaminated diet, alcohol abuse, 
obesity-related fatty liver disease and cirrhosis (Nordenstedt et al., 2010). 
Numerous genetically engineered mouse models have been generated 
mimicking the hot spot mutations frequently found in patients. Moreover, 
chemical induced cancer mouse models have been established to examine the 
mechanism of tumor initiation and promotion as well as anti-cancer therapies 
(Heindryckx et al., 2009, Bakiri et al., 2013). Diethylnitrosamine (DEN) is the 
most widely used chemical to induce liver cancer in mice, as the course of 
cancer development is similar to human HCC. DEN is a potent carcinogen 
that can induce hepatocyte DNA damage. When injected into very young mice 
(with actively proliferating hepatocytes), even a single low dose of DEN is 
able to initiate and cause HCC. However, when administrated to adult mice, a 
much higher dose of DEN and assistance from tumor promoters such as 
phenobarbital (PB) or carbon tetrachloride (CCl4) are required to induce HCC 
(Heindryckx et al., 2009, Bakiri et al., 2013). 
DEN/PB protocol was used to investigate the function of c-JUN in liver 
cancer development. Mice with hepatocyte-specific c-JUN deletion (c-
Junf/f;Alfp-Cretg) as well as mice with hepatocyte and hematopoietic cell-
specific c-JUN deletion (c-Junf/f;Mx-Cretg), both showed dramatically reduced 
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tumor numbers and sizes (Eferl et al., 2003a, Min et al., 2012). Same protocol 
was used to induce liver cancer in c-JunAA/AA mice, whereas no differences in 
terms of tumor formation as well as tumor cell apoptosis were observed (Eferl 
et al., 2003a). These data demonstrated that c-JUN is required, but JNP is not 
required for liver tumor development. 
The mechanism underlining c-JUN promoting liver tumor progression is via 
protection of tumor cells from apoptosis. In fact, c-JUN-deficient liver tumors 
exhibit markedly increased tumor cell death rather than reduced proliferation. 
Two pathways have been proposed to contribute to this situation. First, c-JUN 
can antagonize p53 and its pro-apoptotic target gene Noxa thereby suppressing 
the tumor cell death (Eferl et al., 2003a). On the other hand, c-JUN can also 
suppress c-FOS and its target gene SIRT6, a deacetylase that limits survivin 
promoter acetylation and transcriptional activation. Hence, c-Jun induces the 
expression of the anti-apoptotic survivin thereby promoting hepatocyte 
survival and tumor initiation (Min et al., 2012).  
Taken together, c-JUN appears to be a positive regulator in several kinds of 
liver pathogenesis. Liver fibrosis is a typical response to hepatic injury (e.g. 
hepatocellular death) and occurs in almost all types of liver diseases (Seki et 
al., 2015). Therefore, it is conceivable that c-JUN may play a role in 




1.9 Hepatic fibrosis 





Figure 8. Alterations of hepatic architecture 
(a) In normal liver, HSCs are quiescent vitamin A-storage cells. The perisinusoidal 
space contains low density basement membrane-like matrix; (b) In fibrotic liver, 
HSCs activate, lose their vitamin A droplets, proliferate and migrate, secreting large 
amounts of fibrillar ECM proteins into the perisinusoidal space. Figure adapted from 




Hepatic fibrosis is a common public health problem that affects hundreds of 
millions of patients worldwide. Main risk factors like hepatitis viral infection, 
alcohol abuse and nonalcoholic steatohepatitis (NASH) can cause hepatic 
fibrosis. Advanced hepatic fibrosis can lead to cirrhosis, HCC or other liver-
related morbidity and mortality (Bataller et al., 2005, Schuppan et al., 2013).  
Hepatic fibrosis is defined as the excessive accumulation of fibrillar proteins 
in the perisinusoidal space. It is a dynamic process of imbalanced synthesis 
and degradation of the extracellular matrix (ECM) components. The synthesis 
of the ECM is characterized by both quantitative increase as well as 
qualitative alteration (from the low density basement membrane-like matrix 
shift to the interstitial fibrillar collagens) of the ECM components (Figure 8). 
The degradation of the ECM components is through a family of enzymes 
called matrix metalloproteinases (MMPs). One mode of regulation of MMPs 
is through tissue inhibitor of metalloproteinases (TIMPs), a family of 
proteinases that function to antagonize specific MMPs thus preventing the 
ECM degradation. Therefore MMPs and TIMPs work synergistically to 
regulate the turnover and remodeling of ECM. During fibrosis progression, the 
increased stiffness of ECM forms fibrous scars that progressively substitute 
the functional liver parenchyma, resulting in distorted liver architecture, 
altered liver function and portal hypertension, ultimately leading to 
pathological changes to the organ such as liver cancer (Bataller et al., 2005, 
Friedman, 2008b, Hernandez-Gea et al., 2011).  
Hepatic fibrosis usually results from chronic liver damage and is classified as 
a wound healing response that engages a range of cell types. During liver 
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injury, hepatocytes are the main targets for most hepatotoxic agents and can 
regenerate to replace the dead cells. Damaged hepatocytes release signals like 
ROS, thereby stimulating the accumulation of inflammatory cells as well as 
activation of fibrogenic cells. Acute liver injury activates a transient wound 
healing response and causes limited fibrosis. The fibrotic components will be 
degraded after successful repair of the liver. In contrast, chronic liver injury 
activates a persistent wound healing response with repeated injury and 
healing, thus resulting in excessive accumulation of ECM and fibrosis 
(Bataller et al., 2005, Friedman, 2008b, Hernandez-Gea et al., 2011). 
1.9.2 Hepatic stellate cell is the main fibrogenic cell type 
The fibrogenic cells during liver injury and repair are derived from multiple 
sources including activated HSCs, periportal fibroblasts, bone marrow-derived 
mesenchymal cells and fibrocytes. Activated HSCs have been identified as the 
most dominant source (Friedman, 2008a, Forbes et al., 2011, Hernandez-Gea 
et al., 2011). 
HSCs are a heterogeneous group of cells with similar functions. HSCs are 
formerly described as “lipocytes” based on their features of fat (vitamin A) 
uptake and storage. The name “hepatic stellate cell” has been standardized to 
reflect its resting morphology of a star-like shape found in normal liver 
(Bataller et al., 2005, Friedman, 2008a). 
HSCs are well-known for their role in hepatic injury and repair. Upon liver 
injury, the structure and function of HSCs change dramatically, lose their 
characteristic vitamin A droplets and evolve into contractile myofibroblasts-
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like cells. These activated HSCs proliferate and migrate to the sites of injury, 
producing and secreting large amounts of fibrous proteins to the ECM. Hence 
HSC activation and transdifferentiation are at the center of hepatic fibrosis 
progression (Bataller et al., 2005, Friedman, 2008a, Friedman, 2008b, 
Hernandez-Gea et al., 2011).  
Conceptually, HSC activation consists of two major phases: initiation and 
perpetuation. Initiation results mostly from paracrine stimulation due to 
changes in the surrounding environment such as signals released from 
damaged/dead hepatocytes and activated inflammatory cells. Perpetuation 
involves both paracrine and autocrine loops to maintain and amplify the 
activated phenotypes including loss of vitamin A-storing capacity, 
proliferation, contractility and most importantly fibrogenesis (Friedman, 2000, 
Friedman, 2008a, Friedman, 2008b). 
In order for activated HSC to be detected correctly, various markers such as α-
smooth muscle actin (αSMA), desmin and vimentin have been determined and 
are considered as classical activated HSC markers. Promoters of these 
cytoskeletal proteins, as well as type I collagen and glial fibrillary acidic 
protein (GFAP) have been extensively used by numerous studies to 
specifically drive transgene expression in HSCs (Friedman, 2008a).  
1.9.3 AP-1 and hepatic fibrosis 
Several genes (e.g. TIMP-1, IL-6, Osteopontin etc.) involved in HSC 
activation and hepatic fibrosis are known AP-1 target genes. Specifically, 
JUND knockout mice (Jund-/-) are significantly protected from CCl4-induced 
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hepatic fibrosis and this has been attributed to impaired transcriptional 
activation of TIMP-1 due to the loss of JUND (Smart et al., 2006). 
Additionally, mice with ectopic induction of FRA1 (tetracycline-responsive 
element controlling FRA1) expression develop periportal hepatic fibrosis 
spontaneously. However, absence of FRA1 does not protect fibrosis 
development induced by three independent experimental fibrotic models 
(BDL [bile duct ligation], CCl4 and DDC [3,5-diethoxycarbonyl-1,4-
dihydrocollidine]) (Hasenfuss et al., 2014a).  
Surprisingly, c-JUN's role in hepatic fibrosis has not been delineated albeit 
being a central molecule of the AP-1 family and an essential factor involved in 
multiple aspects of liver physiology. 
1.9.4 Current treatment for hepatic fibrosis 
Till date, despite clinical documentations about the reversal of liver fibrosis or 
even cirrhosis, there is no curative treatment for liver fibrosis. Currently, the 
most efficient way for fibrosis reversal is by removal of the causal agents such 
as denying alcohol intake or antiviral treatments. Moreover, there is evidence 
that once the damage persists for long period, even at a very low level, there is 
a steep decrease in the healing potential. For more serious conditions such as 
cirrhosis with clinical complications, the only approach currently is to undergo 
liver transplantation (Bataller et al., 2005, Schuppan et al., 2013). Hence 
development of effective antifibrotic therapies, including slowing or halting 
the progression of fibrosis or even promoting the regression of fibrosis,  are 
required and might be possible in future. 
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1.10 Hedgehog signaling and liver repair 






Figure 9. Canonical Hedgehog (Hh) signaling 
Canonical Hh signaling pathway and components. Figure adapted from 
Omenetti et al., 2011 Figure 1. 
 
The Hh pathway is a highly conserved signaling pathway involved in 
embryogenesis, development and tissue remodeling. The Hh proteins are 
soluble ligands that include Sonic hedgehog (Shh), Indian hedgehog (Ihh) and 
Desert hedgehog (Dhh). The canonical Hh pathway is illustrated in Figure 9. 
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Patched (Ptc) is a transmembrane receptor that physically interacts with the 
Hh ligands. In the absence of Hh ligands, Ptc represses the activation of 
Smoothened (Smo), thereby preventing Smo from interacting with the 
Glioblastoma (Gli) family of transcription factors (Gli1, Gli2 and Gli3), 
leading to their phosphorylation and subsequent degradation. Upon Hh ligand 
binding, Ptc liberates Smo. The activated Smo in turn permits the stabilization 
and nuclear translocation of the Gli transcription factors. Nuclear 
accumulations of the Gli transcription factors thus regulate the expression of 
Hh-target genes, which include several Hh pathway components such as Ptc, 
Gli1 and Gli2. Gli1 and Gli2 generally function to amplify the Hh signaling, 
whereas Gli3 primarily acts as the signaling repressor. Moreover, Hh-
interacting protein (Hhip) is another transmembrane protein that competes 
with Ptc for binding with Hh ligands and therefore antagonizes Hh signaling 
(Omenetti et al., 2008, Choi et al., 2011, Omenetti et al., 2011). 
1.10.2 Hh-producing cells and Hh-responsive cells 
Hh-producing cells are cells that can synthesize and release soluble Hh ligands 
to the extracellular space. Hh-responsive cells are cells that express the Hh 
receptor Ptc thus are able to interact with the Hh ligands and trigger 
intracellular signaling cascades. Hh pathway activation typically enhances the 
growth and viability of the Hh-responsive cells (Choi et al., 2011, Omenetti et 
al., 2011). 
Hh-producing cells may or may not be Hh-responsive cells themselves. 
Studies have identified that many types of organ stromal cells and progenitor 
cells are Hh-responsive cells whereas the mature epithelial cells are generally 
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not (Omenetti et al., 2008). In the liver, mature hepatocytes are Hh-producing 
cell but not Hh-responsive cell, whereas HSCs are both Hh-producing cell and 
Hh-responsive cell. Therefore Hh-dependent paracrine and autocrine signaling 
can regulate HSC cell fate (Sicklick et al., 2005, Yang et al., 2008, Jung et al., 
2010). 
1.10.3 Hh signaling in adult liver repair 
Adult liver repair requires regeneration of the liver parenchyma to replace 
damaged epithelial cells. Cell lineage tracing has revealed that new 
hepatocytes can be derived from both proliferation of undamaged hepatocytes 
and differentiation of the liver progenitor cells. Liver progenitor cell 
populations are heterogeneous, including Lgr5 positive cells, Sox9 positive 
cells and Keratin 19 (K19) positive cells. Interestingly, quiescent HSCs 
express high levels of Lgr5 and could differentiate into hepatocytes during 
liver repair, hence HSC also functions as a source of liver progenitor cells 
(Swiderska-Syn et al., 2014). 
Healthy adult livers do not exhibit active Hh signaling. Activation of Hh 
signaling occurs rapidly following liver injury. Damaged epithelial cells 
produce Hh ligands; these ligands diffuse away and enter the bile canaliculi 
and liver sinusoids and activate Hh signaling in Hh-responsive cells such as 
HSCs and other liver progenitor cells (Omenetti et al., 2011). The role of 
active Hh signaling in adult liver repair has been investigated in various 
models including methionine choline-deficient, ethionine-supplemented diet 
(MCDE), BDL and PH. Inhibition of Hh signaling by targeted disruption of 
Smo in HSCs in all models significantly reduced HSC activation and 
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attenuated hepatic fibrosis. However, absence of Hh signaling also impaired 
liver repair due to abrogated accumulations of various liver progenitor 
populations (Michelotti et al., 2013, Swiderska-Syn et al., 2014). 
1.11 Aims 
c-JUN was first discovered as a cellular homologue of the retroviral 
oncoprotein v-Jun and as a central molecule of the AP-1 transcription factor 
complex. Since then on, accumulating evidence have surfaced to emphasize 
on c-JUN/AP-1 functions in transcriptional regulation of multiple biological 
processes such as embryonic and tumor development (Mechta-Grigoriou et 
al., 2001, Vogt, 2001). The activity of c-JUN/AP-1 was thought to be 
regulated mainly by N-terminal phosphorylation at serines 63/73 through 
JNKs, which respond to a wide range of stress stimuli in regulating various 
aspects of cellular physiologies including inflammation (Karin, 1995, Karin et 
al., 1997). Till date, deregulated c-JUN expression has been detected in a 
spectrum of diseases and disorders with particular attention in the liver, 
neurons and skin (Shaulian et al., 2002, Eferl et al., 2003b).  
The cellular functions (such as cell proliferation, apoptosis and 
transformation) and the physiological functions (such as development, 
regeneration and tumorigenesis) of c-JUN and its related target genes in 
certain cell/tissue types have been discovered and studied in great detail. 
However, despite the increasing knowledge of c-JUN, its role in several other 
physiological conditions (such as fibrosis) and other cell/tissue types (such as 
adipose tissue) is still not clear and remains to be elucidated. The aim of my 
study is thus to identify and characterize novel c-JUN target genes and 
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biological processes on a global scale, and focus on characterizing in detail a 

















Table 2. Genetically modified mice used in this study 
Mouse Strain 
(Background) 
Genotype Description Source 
c-JUN knockout 
(C57BL/6 × 129) 
c-Jun+/- 
Mouse harboring a frameshift 





(C57BL/6 × 129) 
c-JunAA/+ 
Mouse harboring a mutant c-Jun 
allele with serines 63 and 73 









Mouse carrying floxed c-Jun 
alleles which the c-Jun gene is 
flanked by two loxP sites (Behrens 





(C57BL/6 × 129) 
Mx-Cretg 
Mouse carrying Cre transgenes 
whose expression are controlled by 
an interferon-inducible Mx1 
promoter (Kuhn et al., 1995). 






Mouse carrying CreER transgenes 
which are directed by Col1a2 
promoter. The CreER recombinase 
needs to be activated by tamoxifen 







Freshly isolated primary MEFs were used in this study.  
2.1.3 Drugs and treatments 
Table 3. Drugs and treatments used in this study 
Name Source Catalog No. 
Carbon tetrachloride (CCl4) Sigma 319961 
cis-Diammineplatinum (II) dichloride  
(Cisplatin, CDDP) 
Sigma P4394 
Olive oil Sigma O1514 
Polyinosinic-polycytidylic acid sodium salt  
(Poly I/C) 
Sigma P0913 
Tamoxifen Sigma T5648 
UV Stratalinker® 2400 Stratagene - 
 
2.1.4 Chemicals and Reagents 
Table 4. Chemicals and Reagents used in this study 
Chemicals and Reagents Source Catalog No. 
1-Bromo-3-chloropropane (BCP) Sigma B9673 
Albumin, Bovine (BSA) Amresco 0332 
cOmplete ULTRA Tablets, Mini, EDTA-free  
(protease inhibitor cocktail) 
Roche 05892791001 
Direct Red 80 (Sirius Red) Sigma 365548 
Eosin Y solution, aqueous Sigma HT110232 
Formaldehyde solution min. 37% Merck - 
Hematoxylin Solution, Mayer‟s Sigma MHS16 
Hematoxylin solution A according to Weigert Sigma 03973 
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Hydrochloric acid 37% Sigma 258148 
Phosphatase Inhibitor Cocktail 2 Sigma P5726 
Picric acid solution Sigma P6744 
Propidium iodide (PI) Sigma P4170 
Protein Block Serum-Free Dako X0909 
Proteinase K Amresco 0706 
QuantiFast SYBR Green PCR Kit Qiagen 204057 
SuperScript® II Reverse Transcriptase Invitrogen 18064-014 
Trisodium citrate dihydrate Sigma S1804 
TRIzol® Reagent Invitrogen 15596018 
Tween 20 Sigma 274348 
Xylene Fisher Scientific - 
 
2.1.5 Antibodies 
Table 5. Antibodies used in this study 
Primary Antibodies Usage Source Catalog No 
Annexin V-FITC flow cytometry BD Biosciences 556419 
Anti-Actin immunoblot Sigma A2066 
c-JUN (60A8) immunoblot Cell Signaling 9165 




JNK1/JNK2 immunoblot BD Biosciences 554285 
Phospho-c-JUN (Ser 63) 
II 
immunoblot Cell Signaling 9261 
Phospho-SAPK/JNK 
(Thr183/Tyr185) (G9) 
immunoblot Cell Signaling 9255 
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αSMA immunostaining Abcam AB-32575 
Desmin immunostaining Abcam AB6322 
Ihh immunostaining Abcam Ab39634 
Gli2 immunostaining GenWay Biotech GWB-B3B44 
 
Secondary Antibodies Usage Source Catalog No 
Anti-rabbit IgG, 
HRP-linked 
immunoblot Cell Signaling 7074 
Anti-mouse IgG, 
HRP-linked 
immunoblot Cell Signaling 7076 
Anti-rabbit IgG immunoblot Sigma A9169 
Anti-mouse IgG immunoblot Sigma A2304 
Anti-rabbit, 
HRP-labelled polymer 
immunostaining Dako K4003 
Anti-mouse, 
HRP-labelled polymer 
immunostaining Dako K4001 
 
2.1.6 Homemade solution 
Table 6. Components of homemade solutions used in this study 
Experiment Solution name Components 
Mouse 
genotyping 
Tail lysis buffer 
1% SDS, 50 mM Tris pH 8.0, 10 mM NaCl, 
10 mM EDTA 
TE buffer 10 mM Tris pH 8.0, 1 mM EDTA 
Immunoblot Protein lysis buffer 
1% Nonidet P40, 50 mM Tris pH 7.6, 150 






0.375M Tris pH 6.8, 12% SDS, 60% (v/v) 




0.25 M Tris, 1.92 M Glycine, 1% SDS 
Transfer buffer 
25 mM Tris, 192 mM Glycine, 20% (v/v) 
methanol 
Tris Buffered Saline 
(TBS 20X) 
0.4 M Tris, 2.74 M NaCl, pH 7.6 
Membrane Blocking 
buffer 
5% (w/v) non-fat milk powder in 1XTBS 
with 0.1% (v/v) Tween-20 
Primary antibody 
dilution buffer 




1% (w/v) BSA in 1XTBS with 0.1% (v/v) 
Tween-20 




10 mM Trisodium citrate dihydrate, pH 6.0 
Washing buffer 1XTBS with 0.01% (v/v) Tween-20 
 
2.1.7 Primers 
Table 7. Genotyping primers used in this study 
Strain Primer Sequence 5'-3' Target 
c-JUN 
knockout 










Lox5 CTCATACCAGTTCGCACAGGC - 




12249 TCCAATTTACTGACCGTACACCAA Cre 
transgene 12250 CCTGATCCTGGCAATTTCGGCTA 
oIMR7338 CTAGGCCACAGAATTGAAAGATCT internal 
control oIMR7339 GTAGGTGGAAATTCTAGCATCATCC 
 
Table 8. qRT-PCR primers used in this study 








































































































































































































































































































2.2.1 Mouse breeding  
Mice (above six weeks age) of c-Jun+/-, c-JunAA/+, c-Junf/f, Col-CreERtg and 
Mx-Cretg genotypes were used for breeding in order to generate required 
specific genotypes for experiments. Detailed genotypes of the breeders and 
offspring are shown in the results section. 
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2.2.2 Mouse treatment  
Six-week-old mice were treated twice a week with olive oil or CCl4 (1 μl per 
gram body weight [gbw], diluted in olive oil) by intraperitoneal (i.p.) injection 
for 4, 6 and 8 weeks to induce fibrosis. For c-Junf/f;Col-CreERtg and c-
Junf/f;Col-CreERntg mice, additional treatment with tamoxifen (1 mg per 
mouse) was administrated by gavage to activate the Cre recombinase. For c-
Junf/f;Mx-Cretg and c-Junf/f;Mx-Crentg mice, additional dosage of Poly I/C (13 
μg/gbw) were administrated by i.p. injection to induce the expression of the 
Cre transgenes. All mice were sacrificed 48-72 hour after the last injection 
and their livers were excised, frozen or formalin fixed for further analysis. 
Detailed injection and harvesting schemes are shown in the results section. All 
animal experiments were approved by and performed in accordance with the 
guidelines of the SingHealth's Animal Care and Use Committee. 
2.2.3 Mouse genotyping 
Around 5 mm tail tip of every three-week-old mouse or yolk sacs of 
individual embryos were collected to confirm the mice genotypes. Samples 
were digested overnight in tail lysis buffer with 0.4 mg/ml Proteinase K at 55 
oC. The genomic DNA was precipitated by adding 0.25 volume of saturated 
NaCl and one volume of 2-Propanol. The precipitated genomic DNAs were 
then washed once in 70% ethanol, air dried and resuspended in appropriate 
amount of TE buffer. These purified genomic DNAs were used as templates to 
amplify by polymerase chain reaction (PCR) in order to determine genotypes. 
The genotyping primers are listed in Table 7. 
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2.2.4 Mouse embryo isolation 
Heterozygous c-Jun+/- male and female mice or c-JunAA/+ male and female 
mice were mated and the appearance of the vaginal sperm plug was taken as 
0.5 day post coitum (dpc). Pregnant females were sacrificed at 11.5 or 13.5 
dpc and the embryos were isolated, frozen or formalin fixed, or immediately 
used to prepare MEFs for culture. 
2.2.5 Primary MEF culture and treatment 
MEFs were prepared from embryonic day 11.5 dpc embryos. Briefly, embryo 
yolk sac and head were removed; the rest of the embryo body was 
disaggregated by a 1 ml insulin syringe plunger and filtered with a cell 
strainer. Filtered cells were plated onto one well of a six-well plate in 
Dulbecco‟s modified Eagle‟s medium (DMEM) supplemented with 10% 
serum, 100 units / ml penicillin and streptomycin, 0.1 mM non-essential 
amino acids, 2 mM glutamine, 1 mM sodium pyruvate. MEFs were cultured at 
37oC, 5% CO2 and 3% O2 condition.  
Trypsin-EDTA (0.05%) was used to subculture primary MEFs. Briefly, when 
cells reach 90% confluency, culture media was discarded and the cells were 
washed gently with 1X phosphate buffered saline (PBS). The cells were then 
incubated with appropriate amount of 0.05% Trypsin-EDTA until they 
completely detached from each other as well as the culture plates. The 
detached cells were then resuspended in fresh media and divided accordingly. 
Early-passaged MEFs were seeded onto appropriate areas of culture plates the 
day before treatment. On the treatment day, culture media were discarded and 
62 
 
the cells were washed once with 1X PBS; the washed cells were either 
irradiated with various doses of UV (Stratagene UV Stratalinker 2400) 
followed by addition of fresh culture media or replaced with fresh media 
containing various concentrations of CDDP. The treated cells were further 
incubated and harvested at indicated time points for immunoblot, apoptosis, 
transcriptome and target gene expression analysis. 
2.2.6 Proliferation assay 
At least 4 individual MEF clones were used per genotype to generate the 
growth curve. 1×105 number of MEFs were plated onto six-well plates and  
were counted daily. Independent experiments were performed in duplicates 
and data collected were represented as mean + standard deviation (SD). 
2.2.7 Apoptosis assay 
 MEFs were treated with 40 J/m2 or 80 J/m2 of UV radiation, 15 μM or 30 μM 
of CDDP respectively for 24h prior to harvesting. Both live and dead cells 
were collected, washed once in PBS and incubated with Annexin V-FITC and 
0.5 μg/ml of PI in binding buffer (10 mM HEPES pH 7.4, 0.14 M NaCl, 2.5 
mM CaCl2) for 15 to 30 minutes in the dark at room temperature. Cells were 
analyzed by flow cytometry (Becton Dickinson FACSCalibur) immediately 
after incubation. 
2.2.8 Immunoblot assay 
Cells were harvested, washed once with PBS and lysed for 30 minutes in lysis 
buffer with protease inhibitor cocktail and phosphatase inhibitor cocktail on 
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ice. The suspensions were then spun for 15 minutes at 14000 rpm in 
refrigerated centrifuge and the supernatant was transferred to new tubes for 
further experiments or kept in -80 oC for long term storage.  
50 μg whole cell extracts were separated by 10% SDS-PAGE and transferred 
to PVDF membrane (Millipore). Immunoblotting was performed with the 
following antibodies:  Phospho-c-JUN (Ser 63) II Antibody, c-JUN (60A8) 
Rabbit mAb, Phospho-SAPK/JNK (Thr183/Tyr185) (G9) Mouse mAb, 
JNK1/JNK2 and anti-Actin antibody. Blots were incubated with ECL western 
blotting detection reagent (Amersham) and chemiluminescence was detected 
with Biomax MR X-ray film (Kodak). Detailed information of all the 
antibodies were listed in Table 5. 
2.2.9 RNA extraction 
TRIzol reagent was added to whole mouse embryos, cell pellets, small 
fractions of mouse livers individually and was lyzed by homogenizer, 
vortexing or TissueLyser II (Qiagen) respectively. 0.1 volume of BCP were 
added to separate the lysate into an organic layer and aqueous layer. The 
aqueous layer was pipetted into a new tube along with 2-Propanol, causing 
RNA to be precipitated. The precipitated RNAs were then washed in 75% 
ethanol (prepared in nuclease-free water) to remove impurities, air dried and 
then resuspended in nuclease-free water.  
2.2.10 Transcriptome analysis 
Transcriptome of tissues/cells were analyzed by whole genome expression 
microarrays. In brief, total RNAs were extracted as mentioned above; RNAs 
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were labeled and hybridized on GeneChip® Mouse Genome 430 2.0 Arrays 
(Affymetrix); the hybridized arrays were then washed and scanned to generate 
raw data. All the procedures were performed according to the manufacturer‟s 
instructions.  
Raw data were processed using Partek Genomic Suite software, normalized by 
GC-RMA method to convert into a log2 scale. Differentially expressed genes 
were identified using Analysis of variance (ANOVA) test and filtered with the 
statistical cutoff set at false discovery rate (FDR) <0.05 and fold change (FC) 
>2.0. The Ingenuity Pathway Analysis (IPA) software (www.ingenuity.com) 
was used to analyze the gene ontology and canonical pathways that are 
differentially enriched in the various gene sets. 
2.2.11 Quantitative gene expression assay 
Total RNA was prepared as mentioned above. RNA Concentration was 
determined by NanoDrop and 1-3 μg of total RNA was used to synthesize 
cDNA using SuperScript II reverse transcriptase. 
Quantitative real-time PCR (qRT-PCR) was performed using gene-specific 
primers and QuantiFast SYBR Green PCR Kit in Rotor-Gene Q real-time 
PCR machine (Qiagen) according to manufacturer‟s instructions. 
Relative gene expression was normalized with gapdh expression and fold 
induction was calculated with reference to wild type samples. 
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2.2.12 Histological analysis 
Both the mouse embryo and liver tissue were fixed in 10% formalin for about 
16 hours. The embryo was then cut at the sagittal plane through its midline 
whereas for the liver, each of the four liver lobes were cut and the largest 
piece of each lobes was taken. They are then dehydrated and embedded in 
paraffin blocks. Thereafter, tissue was sectioned at a thickness of 5 μm, placed 
on glass slides and baked in 55oC oven for a few hours. Once the sections 
were ready to be stained, they were deparaffinized in xylene and rehydrated 
gradually by a series of decreasing concentrations of ethanol all the way to 
water. 
For Sirius Red staining, sections were stained with hematoxylin (Weigert's) 
for 8 minutes, washed with running tap water for 10 minutes, followed by 
incubation with 0.1% (w/v) Sirius Red diluted in picric acid solution for 1 
hour. The slides were then rinsed in two quick changes of 0.5% (v/v) acetic 
acid to remove unbound dye.  
For Hematoxylin-Eosin (H&E) staining, sections were first incubated in 
Hematoxylin (Mayer's) for 15 mins, then rinsed in water followed by a rapid 
dunk into 1% (v/v) HCl diluted in ethanol and back into water again, the 
sections were subsequently incubated in Eosin for 1 min. 
For immunostaining, sections were first incubated with 3% hydrogen peroxide 
to block endogenous peroxidase, then heated in sodium citrate buffer to 
retrieve antigen. Sections were then blocked in Dako Protein Block Serum-
Free followed by incubation with specific primary and secondary antibodies  
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(Table 5). Sections were incubated with DAB reagent (Dako) to detect the 
targeted proteins. 
After either one of the stainings, the slides were dehydrated gradually by a 
series of increasing concentrations of ethanol until completely dehydrated in 
absolute ethanol. Lastly, they are soaked in xylene before mounting and 
observed under a light microscope. 
To quantify staining, 20 randomly taken images of 10X fields per section were 
evaluated by MetaMorph (Molecular Devices) software. 
2.2.13 Statistical analysis 
All data are presented as mean+SD. The results were analyzed by unpaired 
Student‟s t-test or ANOVA when appropriate. Statistical calculation was 
performed using GraphPad Prism software. The animal numbers used for each 
experiment are indicated in each of the figure legends. P-value less than 0.05 










Chapter 3  





c-JUN mainly exists in two forms: N-terminal unphosphorylated form and N-
terminal phosphorylated form. The N-terminal phosphorylated form of c-JUN 
generally accumulates in response to various stimuli and is thought to possess 
higher transcriptional activity (Shaulian et al., 2002). However, the 
transcriptional capability of the N-terminal unphosphorylated c-JUN that 
usually occurs at low level under unstimulated condition is unclear. Previous 
studies have revealed that genetic disruption of c-Jun leads to embryonic 
lethality (Hilberg et al., 1993, Johnson et al., 1993). The expression of the 
phosphoacceptor mutant c-JUN (c-JunAA/AA), where serines 63 and 73 are 
changed to alanines, disabling JNP and thus mimicking the N-terminal 
unphosphorylated form of c-JUN, is sufficient to rescue the embryonic lethal 
phenotype of the c-Jun null mice (Behrens et al., 1999). This data suggests 
that the expression of the genes that are essential for the survival of the 
embryo and the adult organism can be efficiently regulated even by the N-
terminal unphosphorylated form of c-JUN. In other words, c-JUN does not 
require JNP for some of its functions. Of note, many studies have also 
demonstrated that under particular stressed conditions, JNP is indeed critical 
for proper c-JUN function in certain cell types (e.g. neurons) (Behrens et al., 
1999, Behrens et al., 2001, Besirli et al., 2005). Collectively, these data 




3.2 Transcriptome profiling of c-Jun+/+, c-Jun-/- and c-JunAA/AA embryos 
To gain insights into how c-JUN functions in a JNP-dependent and -
independent manner, we identified genes that are differentially regulated by 
N-terminal phosphorylated and unphosphorylated c-JUN. To this end, we 
employed c-Jun+/- and c-JunAA/+ mice and bred them accordingly to obtain c-
Jun+/+, c-Jun-/- and c-JunAA/AA mice (Table 9). These mice express wild type c-
JUN (c-JUNWT), frameshift non-functional c-JUN and the N-terminal 
nonphosphorylatable mutant form of c-JUN (c-JUNAA) respectively.  
 
Table 9. Intercross of c-Jun+/- and c-JunAA/+ mice illustrated by Punnett squares 
c-Jun+/- mice were intercrossed to obtain c-Jun+/+ and c-Jun-/- embryos. c-JunAA/+ 
mice were intercrossed to obtain c-Jun+/+ and c-JunAA/AA embryos.  
 
  c-Jun+/- 
 
  c-JunAA/+ 
  c-Jun+ c-Jun-   c-Jun+ c-JunAA 
c-Jun+/- 
c-Jun+ c-Jun+/+ c-Jun+/- 
c-JunAA/+ 
c-Jun+ c-Jun+/+ c-JunAA/+ 
c-Jun- c-Jun+/- c-Jun-/- c-JunAA c-JunAA/+ c-JunAA/AA 
 
We first sought for genes that are regulated differently by c-JUNWT and c-
JUNAA proteins under normal physiological condition by using viable and 
healthy c-Jun+/+, c-Jun-/- and c-JunAA/AA embryos. Previous studies have 
reported that the morphological defects of the liver and heart arise in c-Jun-/- 
embryos at around embryonic day E12.5 (Eferl et al., 1999). Thus we chose 
embryonic day E11.5 as the evaluation time point to avoid secondary effects 
(such as gradual loss of embryo viability) confounding the transcriptome 
profiles of the c-Jun-/- embryos. We randomly picked (1) 3 c-Jun-/- embryos 
with 2 c-Jun+/+ littermate controls from the c-Jun+/- intercrossing; (2) 3 c-
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JunAA/AA embryos with 2 c-Jun+/+ littermate controls from the c-JunAA/+ 
intercrossing; and generated their transcriptome profiles by performing whole 
genome expression arrays of each individual embryo. The whole experiment 
was then repeated with identical numbers and genotypes of embryos as 
mentioned above. The whole genome expression array used in this study is 
Affymetrix GeneChip® mouse genome 430 2.0 array. This array is a type of 
3' in vitro transcription (IVT) expression array that contains 45000 probe sets 
which covers more than 39000 transcripts and variants from more than 34000 
well-characterized mouse genes and UniGene clusters, and thus enables the 








Figure 10. Transcriptome profiles of c-Jun+/+, c-Jun-/- and c-JunAA/AA embryos 
Viable E11.5 embryos were used for whole genome expression arrays. Each circle 
represents one array in PCA mapped scatter plot generated by Partek Genomic Suite 
software. The embryos are colored by genotype: c-Jun+/+ (green), n=8; c-Jun-/- (blue), 
n=4; c-JunAA/AA (red), n=4. Circle size represents the experimental duplicates.  
Ellipsoids are drawn around embryos of the same genotype to illustrate the range of 
their gene expression profiles.  
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Principal component analysis (PCA) is a global analysis of the genome instead 
of any particular gene. It provides an overview of the major factors that 
influence the overall expression pattern of the experiment. Samples that are 
closer together denote that their expression patterns are more alike, whereas 
samples that are far apart imply that their expression profiles are less similar 
across the whole genome (Downey, 2006). PCA mapping of the transcriptome 
profiles of all the embryos (Figure 10) revealed that, albeit individual 
variance, embryos of the same genotype exhibited a rather similar global 
expression pattern thus could be clustered together whereas embryos of 
different genotypes displayed a rather dissimilar global expression pattern. 
These suggested that the major factor contributing to the global expression 
differences of the embryos was genotype.  
To obtain the differential gene expressions between c-Jun+/+, c-Jun-/- and c-
JunAA/AA embryos, we performed ANOVA analysis followed by contrasting 
the transcriptome profiles between (1) c-Jun+/+ and c-Jun-/- samples (2) c-
Jun+/+ and c-JunAA/AA samples with a statistical cutoff set at FDR <0.05 and 
FC >1.5. While the PCA plot implied global expression differences between 
different genotypes, to our surprise, we detected no statistically significant 
changes in gene expression profiles between c-Jun+/+ and c-Jun-/- samples, as 
well as between c-Jun+/+ and c-JunAA/AA samples (data not shown).  
Although the PCA plot indicated interesting differences between the different 
genotypes, we were unable to obtain statistically significant differentially 
expressed genes. The reasons behind that could be (1) sample size is not big 
enough; (2) the E11.5 day embryos is too early to exhibit the gene expression 
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differences although it is the most ideal time point as morphological defects 
start to appear at E12.5 day in the c-Jun null embryos; (3) organ-specific gene 
expression differences are nullified due to the dilution effect; (4) the gene 
expression differences are too subtle to be detected due to low expression 
level of c-JUN under normal physiological condition. 
3.3 Transient and sustained c-JUN activation upon stresses 
Although the endogenous levels of both N-terminal unphosphorylated and 
phosphorylated c-JUN are very low under normal physiological condition, 
they can be robustly induced by various stimuli (Vogt, 2001). Unfortunately, it 
is not possible to stimulate viable embryos to induce their endogenous c-JUN 
levels. We therefore sought to identify the gene expression differences in a 
more simple system by utilizing primary MEFs isolated from E11.5 c-Jun+/+, 
c-Jun-/- and c-JunAA/AA embryos, as it is a rather homogenous system and the c-
JUN levels can be manipulated by applying stresses. 
As c-JUN-deficient cells exhibit severe proliferation defects and undergo very 
early senescence in conventional cell culture condition (21% O2) (Johnson et 
al., 1993, Schreiber et al., 1999), we couldn‟t acquire sufficient numbers of c-
Jun-/- MEFs for further treatment. To overcome this problem, we cultured 
primary MEFs in low oxygen (3% O2), which mimics the normal 
physiological condition as suggested by MacLaren et al. (MacLaren et al., 
2004) and successfully expanded MEFs of all genotypes for several passages. 
Interestingly, analysis of the cellular proliferation rate by counting the 
cumulative number of cells over several days revealed that c-Jun-/- and c-
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JunAA/AA MEFs still showed slightly slower proliferation rates (albeit not 
significant) compared to c-Jun+/+ MEFs in 3% O2 condition (Figure 11). 
 
Figure 11. c-Jun+/+, c-Jun-/- and c-JunAA/AA MEFs show comparative proliferation 
rates in 3% O2 condition 
Cells were seeded at 1.0×105 in 6-well plates and cumulative cell numbers were 
counted daily. Experiments were done in duplicates, mean values of all clones of the 
same genotype are shown plotted against time, error bars indicate SD. (A) Sibling 
MEFs from the c-Jun+/- mice intercross were used to plot the growth curve: c-Jun+/+ 
(green), n=5; c-Jun-/- (blue), n=5. (B) Sibling MEFs from the c-JunAA/+ mice 





We treated the early-passaged MEFs with either UV or CDDP to induce c-
JUN as well as JNP because both stresses are known to activate c-JUN in a 
JNK-dependent manner (Kharbanda et al., 1995, Zanke et al., 1996). Next, we 
investigated the level of serines 63/73 phosphorylated c-JUN, total c-JUN, 
phosphorylated JNK and total JNK at different treatment time points 
respectively by immunoblots. As shown in Figure 12A and B, c-JUN 
expression was very low under unstimulated condition. UV irradiation (Figure 
12A) induced an immediate activation of JNK, seen by the rapid increase of 
the phosphorylated JNK level by 1 hour following UV treatment. However 
this induction was not sustained overtime. The phosphorylated JNK level 
decreased back to its original state 4 hours after UV treatment. The total JNK 
level remained constant all the time. Like its upstream kinase JNK, 
phosphorylated c-JUN induction was also rapid and transient following UV 
irradiation, whereas the total c-JUN accumulation occurred in a more 
sustained manner. In contrast to UV, treatment with CDDP (Figure 12B) did 
not cause a rapid induction of both c-JUN and JNK. In fact, the 
phosphorylated forms of c-JUN and JNK were only prominent 4 hours after 
CDDP treatment. Nevertheless the activation of both c-JUN and JNK was 
much more prolonged as compared to UV treatment. Congruently, both c-
Jun+/+ and c-JunAA/AA MEFs exhibited similar kinetics of c-JUN and JNK 
activation. Thus, to ensure the abundance of both total and N-terminal 
phosphorylated c-JUN in MEFs, we chose 1 and 4 hour for UV treatment, 4 






Figure 12. UV and CDDP are transient and sustained c-JUN activating signals 
MEFs of the indicated genotypes were isolated from E11.5 day embryos. MEFs were 
treated with 40 J/m2 of UV radiation (A) or 30 µM of CDDP (B) and harvested at the 
indicated time points. Total cell extracts were prepared and subjected to immunoblot 





3.4 Transcriptome profiling of c-Jun+/+, c-Jun-/- and c-JunAA/AA MEFs 
Having determined the appropriate treatments and time points to elevate the 
endogenous c-JUN and JNP levels, we prepared primary MEFs from 
littermate E11.5 c-Jun+/+ and c-Jun-/- embryos, as well as from littermate 
E11.5 c-Jun+/+ and c-JunAA/AA embryos and treated them as specified earlier. 
Four individual MEF clones of each specific c-Jun genotype were used in this 
experiment. Transcriptome profiles of untreated as well as UV or CDDP-
treated MEFs of various c-Jun genotypes were then generated.  
PCA mapping of all the samples is shown in Figure 13A. Ellipsoids were 
drawn according to the specific treatment and time point to facilitate 
visualization. Interestingly, samples from the same treatment and time point 
were close enough to be grouped together albeit they bear different genotypes. 
Moreover, the ranges of individual groups hardly overlapped one another. 
This data indicated that alterations of stress type and duration resulted in a 
shift in global gene expression. 
Further PCA mapping of untreated and UV-treated samples (Figure 13B, left 
panel) with ellipsoids drawn around each genotype revealed that c-Jun-/- 
samples (blue) formed a distinctly separate group with completely no overlap 
to either c-Jun+/+ (green) or c-JunAA/AA (red) samples, whereas the groups 
formed by c-Jun+/+ and c-JunAA/AA samples exhibited high degree of 
overlapping. Likewise, PCA mapping of untreated and CDDP-treated samples 
(Figure 13B, right panel) also arranged the c-Jun-/- samples (blue) into a 
completely separate group, far apart from the c-Jun+/+ (green) and c-JunAA/AA 






Figure 13. Transcriptome profiles of c-Jun+/+, c-Jun-/- and c-JunAA/AA MEFs 
Untreated and UV/CDDP treated MEFs were used for whole genome expression 
arrays. PCA mapping of (A) all the untreated and treated samples; (B) untreated and 
UV-treated samples (left); untreated and CDDP-treated samples (right). Each circle 
represents one array. The samples are colored by genotype and ellipsoids are drawn 
to group samples: untreated (black); UV-treated (light grey); CDDP-treated (dark 
grey); c-Jun+/+ (green); c-Jun-/- (blue); c-JunAA/AA (red). (C) Source of variation 




and c-JunAA/AA samples as compared to UV-treated samples. These results 
suggested a profound global gene expression differences between c-Jun+/+ and 
c-Jun-/- samples. Strikingly, while c-Jun+/+ and c-JunAA/AA samples also 
exhibited difference in their global gene expression profiles, this difference 
appeared less profound. 
We also performed source of variation analysis to measure the impact of all 
the known variation factors in affecting the global expression values in this 
experiment. The known variation factors include mouse strain, genotype, 
treatment, time point and their interactive effect. The respective contributing 
percentage of each factor is shown in Figure 13C: mouse strain 13.31%, 
genotype 15.19%, treatment 6.64%, time point 13.21% and interactive effect 
16.24%. While the interactive effect from all the factors contributed the most 
in global gene expression changes, „genotype‟ appeared as the single most 
influencing factor that caused the global expression alterations, highlighting 
the significance of c-JUN and JNP in affecting the global gene expression. 
Taken together, these data suggested that deletion of c-JUN affects the global 
transcriptome profiles more dramatically, whereas inactivation of JNP does 
not affect gene expression as much as absence of c-JUN.  
3.5 Identification of c-JUN and JNP-dependent genes 
To avoid complications arising from different genetic background, we did not 
contrast the transcriptome profiles between c-Jun-/- and c-JunAA/AA samples as 
they were derived from different mouse strains. Instead, we contrasted the 
transcriptome profiles between littermate c-Jun+/+ and c-Jun-/- samples and the 
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transcriptome profiles between littermate c-Jun+/+ and c-JunAA/AA samples to 
obtain genes expressed differently among the c-Jun+/+, c-Jun-/- and c-JunAA/AA 
samples. Hence, genes expressed differently between c-Jun+/+ and c-Jun-/- 
samples were considered as c-JUN-dependent genes, while genes expressed 
differently between c-Jun+/+ and c-JunAA/AA samples were considered to be 
JNP-dependent genes. As indicated in Table 10, a large number of genes were 
found to express differentially between c-Jun+/+ and c-Jun-/- samples. On the 
contrary, very few genes exhibit differential expression between c-Jun+/+ and 
c-JunAA/AA samples. These results are consistent with our previous findings that 
absence of JNP does not affect gene expression as much as absence of c-JUN. 
The complete gene lists are submitted as a soft copy. 
 
 
Table 10. Number of c-JUN-dependent genes and JNP-dependent genes 
























To verify the whole genome expression array data, we selected many c-JUN-
dependent genes and JNP-dependent genes and performed qRT-PCR assays 
by using the same RNA samples used for the whole genome expression 
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arrays. The quantified gene expression values were normalized to the 
expression of the housekeeping gene Gapdh. To determine whether the 
expression of these genes were altered by c-JUN or JNP, the relative 
expression difference (FC) of each individual gene was calculated as follows: 
(1) littermate c-Jun+/+ versus c-Jun-/- samples; (2) littermate c-Jun+/+ versus c-
JunAA/AA samples. The complete qRT-PCR validation results are shown in 
Table 11 with indications of significance calculated by student t-test. 
 




c-Jun+/+ vs. c-Jun-/- c-Jun+/+ vs. c-JunAA/AA 
FC p-value FC p-value 
9830001H06RIK -1.006 0.9763 ns -1.336 0.026 * 
Agtr1b -10.623 0.2346 ns -2.050 0.1799 ns 
Ambra1 -1.507 0.3913 ns 1.231 0.1873 ns 
Angptl2 2.147 0.0355 * 1.428 0.0053 ** 
Arl13b -1.106 0.6008 ns -1.088 0.6909 ns 
C1qa 15.572 0.0041 ** 1.644 0.0354 * 
C1qb 27.585 0.0010 ** 1.433 0.0151 * 
C1qc 22.056 0.0031 ** 1.627 0.0148 * 
C3ar1 3.290 0.0040 ** 1.212 0.6681 ns 
Cd14 1.866 0.1601 ns 1.022 0.9702 ns 
Cp -1.166 0.8675 ns -1.985 0.4496 ns 
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Dcn -6.236 0.0287 * 1.095 0.788 ns 
Dock11 -1.113 0.5677 ns 2.048 0.0026 ** 
Dyrk1a -1.042 0.8176 ns -1.036 0.7097 ns 
Elk3 -1.551 0.1295 ns 1.016 0.927 ns 
Emilin2 4.710 0.0017 ** 1.095 0.1627 ns 
Eml4 -1.248 0.4646 ns -1.095 0.7071 ns 
Erc2 2.667 0.0017 ** 1.837 0.0020 ** 
Fam174b -3.581 0.0449 * 1.073 0.7963 ns 
Fermt3 2.208 0.0226 * 1.035 0.9476 ns 
Fgf1 -2.319 0.4214 ns -1.582 0.3493 ns 
Flt4 9.045 0.0376 * 1.883 0.0708 ns 
Glt25d1 -1.272 0.0964 ns 1.465 0.0498 * 
Gpr1 -1.107 0.7425 ns 1.265 0.1381 ns 
Gtf3c1 1.002 0.9917 ns -1.191 0.2473 ns 
Hipk2 -1.766 0.0231 * 1.103 0.1341 ns 
Hjurp -1.086 0.7501 ns 3.100 0.013 * 
Il1rl1 8.994 0.0426 * 1.503 0.0526 ns 
Il4ra 1.654 0.0548 ns 1.305 0.1432 ns 
Kif13b -1.366 0.4519 ns -1.141 0.5983 ns 
Laptm5 9.841 0.0088 ** 1.213 0.3062 ns 
Nfia -2.245 0.2165 ns 1.286 0.4732 ns 
Nppb 3.968 0.0403 * 2.182 0.0058 ** 
Pdgfra -5.234 0.1584 ns -1.335 0.6613 ns 
Pik3r1 -3.326 0.0394 * -1.253 0.5262 ns 
Sh3rf1 -1.309 0.3562 ns 2.294 0.0014 ** 
Slc7a2 -1.988 0.2822 ns -1.273 0.5739 ns 
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Sparcl1 -5.293 0.0455 * 1.833 0.1426 ns 
Tacc3 1.138 0.5707 ns -1.207 0.9285 ns 





c-Jun+/+ vs. c-Jun-/- c-Jun+/+ vs. c-JunAA/AA 
FC p-value FC p-value 
1500004F05Rik 1.665 0.0751 ns 1.540 0.0367 * 
Ablim1 -1.667 0.0881 ns -1.674 0.0553 ns 
Angptl2 2.229 0.0005 *** 1.448 < 0.0001 *** 
Arid5b -1.569 0.2743 ns 1.070 0.8703 ns 
BC023969 -1.382 0.1186 ns 2.008 0.1455 ns 
Dcn -5.996 0.0157 * 1.006 0.9760 ns 
Glt25d1 -1.124 0.3836 ns 1.303 0.0317 * 
Hjurp -1.174 0.6125 ns 1.426 0.1812 ns 
Ica1 2.346 0.0178 * 1.173 0.4785 ns 
Nppb 4.026 0.0040 ** 1.973 0.0025 ** 
Plscr2 -2.412 0.0483 * -1.273 0.2182 ns 
Prnd 3.269 0.0250 * 1.146 0.2712 ns 








c-Jun+/+ vs. c-Jun-/- c-Jun+/+ vs. c-JunAA/AA 
FC p-value FC p-value 
2610528A11Rik 1.326 0.3133 ns 1.439 0.3675 ns 
Ablim1 -3.379 0.0148 * -1.283 0.1782 ns 
Ampd1 1.398 0.1945 ns 1.377 0.1027 ns 
Angptl2 2.621 < 0.0001 *** 1.310 0.0406 * 
Arhgap5 -1.616 0.0258 * -1.062 0.6703 ns 
Chd7 1.612 0.2205 ns 1.129 0.4755 ns 
Cpeb4 -1.209 0.2999 ns -1.117 0.3801 ns 
Ctrl 1.030 0.8752 ns 1.291 0.0401 * 
Cyp1b1 -2.008 0.0677 ns -2.042 0.1305 ns 
Dcn -6.070 0.0062 ** 1.166 0.4826 ns 
Depdc1a -1.345 0.3227 ns -1.460 0.3314 ns 
E030042N06Rik -1.728 0.0052 ** 1.120 0.3958 ns 
Elavl1 -1.038 0.7848 ns 1.104 0.2777 ns 
Enpp1 -1.211 0.2782 ns 1.141 0.4088 ns 
Erc2 1.454 0.1999 ns 1.402 0.0849 ns 
Erlin1 -1.003 0.9900 ns -1.082 0.5917 ns 
Gabpb2 -1.310 0.1855 ns 1.095 0.3628 ns 
Gdf9 1.191 0.4455 ns 1.751 0.0161 * 
Gm5544 1.480 0.0747 ns 1.476 0.0616 ns 
Gsto2 1.284 0.4445 ns 2.169 0.0062 ** 
Glt25d1 -1.380 0.0269 * 1.324 0.0148 * 
Hjurp -1.463 0.1535 ns 1.230 0.4996 ns 
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Hoxa5 -1.870 0.0957 ns -1.607 0.0792 ns 
Igf2 -1.734 0.3200 ns 2.025 0.0267 * 
Itsn1 -1.798 0.0460 * -1.084 0.6979 ns 
Mapk8 -1.958 0.0327 * -1.476 0.1833 ns 
Nasp -1.014 0.9491 ns -1.091 0.6368 ns 
Nefl 8.173 0.0190 * 1.435 0.1620 ns 
Nppb 4.850 0.0193 * 2.645 0.0016 ** 
Ola1 1.100 0.5384 ns -1.159 0.1594 ns 
Pcmtd2 -1.856 0.0924 ns -1.472 0.1601 ns 
Plscr2 -2.666 0.0422 * -1.207 0.3485 ns 
Pogk -1.616 0.1489 ns -1.330 0.2762 ns 
Prrc1 -1.613 0.0211 * 1.027 0.8394 ns 
Ptger1 -2.566 0.1034 ns -1.187 0.0879 ns 
Pus3 -1.494 0.0551 ns -1.055 0.7192 ns 
Rad21 -1.197 0.4875 ns -1.657 0.1178 ns 
Rcan1 1.477 0.2603 ns 1.452 0.0129 * 
Scd2 -1.335 0.3541 ns -1.409 0.1399 ns 
Sdcbp -1.298 0.0953 ns -1.063 0.5187 ns 
Sema7a -1.041 0.8923 ns -1.019 0.9543 ns 
Shd -1.269 0.2309 ns 1.384 0.0413 * 
Tigd3 1.266 0.6996 ns -2.017 0.2143 ns 
Tm9sf2 -1.319 0.1988 ns -1.667 0.0234 * 
Tnfrsf11b -2.531 0.0399 * -1.227 0.0852 ns 
Vwce 1.019 0.8924 ns 1.147 0.4060 ns 
Wrn -1.600 0.2287 ns -1.544 0.2792 ns 
Ywhaz 1.021 0.9215 ns -1.022 0.8590 ns 
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Representative genes whose expressions were significantly altered by c-JUN 
and/or JNP are shown in Figure 14A. Gene Laptm5 is regulated by c-JUN but 
not JNP (littermate c-Jun+/+ versus c-Jun-/-: FC=9.841 [p=0.0088**]; 
littermate c-Jun+/+ versus c-JunAA/AA: FC=1.1213 [p=0.3062]). Gene Hjurp is 
regulated by JNP but not c-JUN (littermate c-Jun+/+ versus c-Jun-/-: FC=-
1.086 [p=0.7501]; littermate c-Jun+/+ versus c-JunAA/AA: FC=3.100 
[p=0.013*]). Gene Erc2 is regulated by both c-JUN and JNP (littermate c-
Jun+/+ versus c-Jun-/-: FC=2.667 [p=0017**]; littermate c-Jun+/+ versus c-
JunAA/AA: FC=1.837 [p=0.0020**]). 
We have thus grouped the validated genes with significant FC into three 
categories based on their expression regulation by c-JUN and/or JNP and is 
illustrated in Figure 14B. (1) genes such as Laptm5, Flt4, Sparcl1 and Dcn,  
come under the category of genes whose transcription was mediated by N-
terminal unphosphorylated c-JUN, whereas JNP did not further 
enhance/suppress their transcription. (2) genes like Hjurp, Sh3rf1, Dock11 and 
Glt25d1 belong to the category of genes whose transcription was only 
modulated by N-terminal phosphorylated c-JUN. (3) genes like C1qa, C1qb, 
C1qc, Nppb, Erc2 and Angptl2 were classified under the category of genes 
whose transcription was regulated by both N-terminal unphosphorylated and 
phosphorylated c-JUN. These data demonstrated that the N-terminal 
unphosphorylated c-JUN is sufficient to regulate gene transcription.  
Intriguingly, while the expression of the second group of genes (e.g. Hjurp, 
Sh3rf1, Dock11) could be modulated by N-terminal phosphorylated c-JUN, 
their expression was not affected by absence of c-JUN. One possibility is that 
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these genes may not be direct targets of c-JUN, but targets of other 
transcription factors that can only cooperate with N-terminal phosphorylated 
c-JUN but not N-terminal unphosphorylated c-JUN.  
In general, the number of JNP-dependent genes are much lesser than the 
number of the c-JUN-dependent genes. This suggests that JNP is not critical 
for c-JUN function in gene transcription in MEFs under both basal and 
genotoxic stressed conditions. Furthermore, detailed gene descriptions, 
functions and related diseases of all validated JNP-dependent genes are 
summarized and shown in Table 12.  
The chromatin binding sites of c-JUN have been mapped previously in K562, 
a human myelogenous leukemia cell line, by using chromatin 
immunoprecipitation-sequencing technique. Several gene regulatory regions 
that were bound by c-JUN have thus been identified in normal unstimulated 
K562 cells (Raha et al., 2010). Therefore, we converged the gene lists 
encompassing c-JUN-dependent genes from our MEFs expression array data 
with genes whose regulatory regions were found to be bound by c-JUN in the 
study mentioned above (GSM487425). We discovered many genes that are 
both bound and regulated by c-JUN and these genes are considered as direct c-
JUN targets. The complete list of these genes and their expression differences 
between c-Jun+/+ and c-Jun-/- cells are shown in Table 13. However, it is 
worth mentioning that different cell types exhibit distinct gene expression 
profiles, hence certain genes that were found to be bound by c-JUN in the 









Figure 14. qRT-PCR verification of subset of c-JUN and JNP-dependent genes 
c-Jun+/+, c-Jun-/- and c-JunAA/AA MEFs (n=4 for each genotype) used for the whole 
genome expression arrays were also used for qRT-PCR validation. (A) Relative 
expression of the representative genes. c-Jun+/+ (green); c-Jun-/- (blue); c-JunAA/AA 
(red). (B) FC values of the c-JUN-dependent genes (black) and JNP-dependent genes 
(grey). FC was calculated by littermate  𝑐−𝑗𝑢𝑛 +/+
𝑐−𝑗𝑢𝑛 −/−  or littermate  𝑐−𝑗𝑢𝑛 +/+𝑐−𝑗𝑢𝑛𝐴𝐴 /𝐴𝐴 . Positive 
FC value represents upregulation in c-Jun+/+ samples, negative FC value represents 
downregulation in c-Jun+/+ samples. All the c-JUN-dependent and/or JNP-dependent 





Table 12. Summaries of validated JNP-dependent genes.  
Information compiled from NCBI (www.ncbi.nlm.nih.gov) and Genecards (www.genecards.org). 
 
Gene Symbol Description Biological functions and processes Location Disease associated 
Angptl2 
Member of the vascular 
endothelial growth factor 
family 

















Hepatic insulin resistance 
C1qb 
C1qc 















Erc2 PDZ domain binding Regulates neurotransmitter Cytoplasm Melanoma 
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Member of the TGF-β 
superfamily 
Cytokine and growth factor activity 




















Omega class glutathione 
S-transferase 

















Chromosome segregation Kinetochore 
Igf2 
Member of the insulin 
family of polypeptide 
growth factors 
Involved in development and growth 












Member of the natriuretic 
peptide family 
Negative regulation of angiogenesis  
Regulation of blood pressure, blood vessel size, 




Various cardio and renal 
disorders 
Rcan1 




Central nervous system development 
Involved in locomotory behaviour 
Skeletal muscle fiber development 
Cytoplasm 
Nucleus 





Sh3rf1 Contains RING and SH3 Scaffold for JNK signaling pathway Cytoplasm Benign paroxysmal 
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Table 13. List of genes that are both bound and regulated by c-JUN 
Gene  
Symbol 
Whole genome expression array (c-Jun-/- vs. c-Jun+/+) 
Untreated UV treated CDDP treated 
p-value FC p-value FC p-value FC 
ABCC1 0.001008 -1.74962 0.000332 -1.58455 0.003726 -1.38341 
ACOT7 1.47E-05 -2.19684 3.23E-07 -2.33372 4.62E-07 -2.26038 
AMBRA1 0.002423 1.65968 0.948374 -1.00593 0.732739 1.03176 
BCAT1 0.009371 -2.19913 0.000345 -2.51374 0.000888 -2.24869 
BCL2L1 0.008315 -1.77567 0.223386 -1.17442 0.272625 1.15464 
BTG2 0.005207 1.85695 0.774629 -1.03686 0.049749 -1.31589 
CAPG 0.001097 -3.40731 0.000188 -3.00195 3.73E-05 -3.81884 
CARHSP1 0.004504 -1.51857 3.41E-05 -1.77386 2.57E-05 -1.8087 
CAST 0.004526 -1.55207 0.000402 -1.55862 8.40E-05 -1.71887 
CDC45 0.002471 -1.73149 0.003679 -1.4398 0.000281 -1.69443 
CLASP1 0.001598 1.93861 0.783174 -1.03136 0.291819 1.12925 
CPEB3 1.22E-05 2.0981 0.284147 1.07726 0.089902 1.1314 
CTPS 0.000968 -1.57903 0.000536 -1.41986 0.065949 -1.15566 
CTSB 0.002153 -1.83612 0.00074 -1.65162 0.000333 -1.74887 
CUBN 0.004273 -1.64409 0.172043 -1.15105 0.700961 -1.03852 
CUX1 0.005759 1.51789 0.012569 1.29193 0.004153 1.36575 
DTX4 0.005212 -1.57813 0.814746 -1.02206 0.055231 -1.21748 
E2F7 0.006155 -1.97809 0.00076 -1.94489 0.203165 -1.20926 
EIF2B3 0.000241 -1.63166 3.87E-06 -1.75848 0.000259 -1.40903 
EIF5 0.003027 -1.57006 0.021349 -1.25072 0.07483 -1.17727 
EIF6 0.002243 -1.60679 0.000258 -1.57426 0.000546 -1.50812 
ELOVL5 0.001959 1.54372 0.000228 1.51222 5.19E-05 1.64349 
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EPT1 0.00275 -1.72266 0.001016 -1.56218 0.280629 -1.11759 
ERC2 0.001084 -2.25708 0.001009 -1.78882 0.111714 -1.24786 
FAM115A 0.000379 1.94754 0.161112 1.14584 0.841664 -1.01861 
FAM174B 0.001622 3.02345 7.69E-05 3.23388 4.16E-05 3.53927 
FGF1 2.32E-06 3.28253 2.49E-07 2.91174 0.593551 1.04947 
FILIP1L 0.002346 -2.02685 0.000517 -1.86073 0.012674 -1.45399 
FOSL1 0.006757 -4.48834 0.221279 -1.50262 0.249408 -1.46482 
FYCO1 0.004602 1.64758 0.346581 1.10079 0.650923 1.04639 
GARS 0.000406 -1.55752 4.62E-05 -1.50914 0.000136 -1.43421 
GNA12 0.004302 -1.73934 0.004558 -1.47355 0.00644 -1.44135 
GNAL 0.00695 -1.61943 0.017318 -1.33218 0.00018 -1.78789 
GSN 0.008333 -1.78287 0.000541 -1.86498 0.001553 -1.71075 
HCFC1R1 0.000958 1.53624 9.77E-05 1.50646 2.86E-05 1.60802 
HIPK2 0.008904 2.03966 0.000541 2.17627 0.000478 2.20486 
HN1 7.43E-05 -1.50251 4.79E-06 -1.48548 2.23E-06 -1.53844 
HSPA9 9.58E-05 -1.51679 9.18E-06 -1.4744 4.32E-05 -1.38315 
IGF1 0.009105 2.7119 0.026656 1.76478 0.008923 2.03003 
IL1RL1 0.007225 -20.672 0.000347 -29.3137 0.001005 -18.5516 
ITPR3 5.86E-05 -3.53237 1.54E-06 -3.85998 3.73E-05 -2.56457 
JAZF1 0.008435 1.80651 0.000503 1.90646 0.001299 1.75948 
KIF1B 0.006716 -1.66472 0.001768 -1.56332 0.407314 1.09588 
KLK8 0.000455 -7.43455 1.01E-05 -9.55872 1.22E-05 -9.11724 
LAPTM5 0.004183 -36.8369 0.000262 -44.8133 0.000283 -43.0941 
LASS4 0.004162 1.57242 0.000478 1.55328 0.006363 1.34707 
LRRC59 7.28E-05 -1.8398 2.60E-06 -1.88225 4.41E-05 -1.58084 
LRRFIP1 0.003256 -2.15935 0.000426 -2.07683 0.187324 -1.22208 
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LTBP1 0.00153 -2.04244 0.002096 -1.61888 0.261317 -1.14959 
MAP3K5 0.00372 2.83462 0.032557 1.62553 0.484692 1.15277 
MAPK13 0.000484 -4.23554 5.43E-06 -5.79521 8.57E-06 -5.30763 
MASP1 0.001798 -1.55322 0.00019 -1.52788 0.000973 -1.40563 
MASTL 0.002686 -2.07678 0.002781 -1.67188 0.045874 -1.34631 
MSI2 0.000111 2.27338 0.700273 1.03824 0.755364 -1.0308 
MTHFD1L 0.001517 -1.89239 0.000204 -1.80976 0.000456 -1.70551 
MYO1D 0.008121 1.75645 0.00321 1.59337 0.000218 1.97642 
NADK 0.009931 -1.68656 0.004266 -1.53461 0.001552 -1.65084 
NEK2 0.003642 -1.87635 0.002261 -1.61548 0.003436 -1.56704 
NFIA 0.001437 3.39338 4.18E-05 3.93483 0.000166 3.18132 
NFIC 0.002328 1.50717 0.007213 1.27239 0.837434 1.0152 
NOC4L 0.008439 -1.87212 0.025812 -1.42571 0.034732 -1.39262 
NR4A1 0.003415 3.6907 0.522112 1.17428 0.70568 1.0987 
NR6A1 0.000615 1.62847 0.812334 1.01727 0.547037 1.04475 
NUBP1 0.005098 -1.57193 0.000738 -1.53553 0.001285 -1.48646 
PANX1 0.009318 -1.93251 0.002935 -1.76232 0.037991 -1.41437 
PCOLCE2 0.000597 -8.81131 1.61E-05 -11.1309 0.000171 -6.13249 
PHF21A 3.51E-05 1.59752 0.40407 1.04179 0.977752 -1.00134 
PIP4K2A 1.76E-08 1.70099 0.924625 -1.00227 0.926157 -1.00222 
PLTP 0.007659 1.94857 0.001217 1.88197 0.001633 1.83247 
PLXNA2 0.000532 1.97609 0.017219 1.31553 0.423027 1.08367 
PPP1R10 0.004679 2.02676 0.825574 -1.0317 0.226489 -1.19456 
PRC1 0.000219 -1.57466 0.000641 -1.32113 5.51E-05 -1.46381 
PTRH1 2.87E-05 -1.73057 2.38E-06 -1.6725 5.60E-05 -1.43079 
RAB30 0.001924 1.51593 0.001093 1.3767 0.073493 1.15154 
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RAD18 0.000135 -1.70572 0.010687 -1.21847 0.8791 -1.0099 
RAI14 0.002116 2.35066 0.89931 1.01928 0.345944 1.15662 
RANGAP1 0.008153 -1.57067 0.011204 -1.35132 0.001607 -1.51519 
RAPGEF4 0.002865 1.7691 0.015162 1.3512 0.504954 1.07375 
RCC1 0.008506 -1.72402 5.03E-05 -2.21794 0.541167 -1.07749 
RGS20 0.0032 -4.82135 0.000445 -4.39695 0.003766 -2.95529 
RIN1 0.001641 -2.02857 0.002974 -1.57878 0.936046 -1.00969 
RORA 0.000603 2.74021 0.003035 1.75522 0.006634 1.6391 
RRAS2 5.72E-05 -2.32442 1.43E-06 -2.47795 0.005241 -1.37538 
RRM2 0.005652 -1.98131 0.002729 -1.72368 0.031185 -1.41234 
SCMH1 7.46E-07 1.70164 0.751197 -1.01135 0.985895 1.00063 
SERPINE1 0.009515 -2.43829 0.00435 -2.05904 0.22691 -1.28878 
SGK1 0.002582 -4.17961 0.022921 -1.97651 0.152734 -1.48117 
SGMS1 0.005583 -1.65222 0.086507 -1.21166 0.409372 1.09087 
SLC1A5 0.004537 -2.30127 0.000319 -2.38188 0.001344 -2.03751 
SLC20A1 0.007599 -2.13115 0.007638 -1.70669 0.118773 -1.31525 
SLC25A13 0.007261 -1.94282 0.036876 -1.40013 0.164709 -1.23323 
SMARCAL1 0.00246 1.51216 2.36E-05 1.71209 0.044358 1.18226 
SNHG3 0.00098 -2.45641 6.80E-05 -2.45818 4.23E-06 -3.45666 
SOX5 0.002125 2.72246 0.243795 1.23818 0.776291 1.05165 
SPAG9 0.000244 1.61393 0.831805 -1.01339 0.977326 -1.00178 
STIM1 0.003622 1.627 0.006817 1.36272 0.082383 1.19234 
STIP1 0.000323 -1.51424 0.000236 -1.35739 0.000407 -1.32918 
STK39 0.008745 -1.57682 0.000231 -1.74024 0.001325 -1.54759 
STXBP4 0.009539 1.67728 0.836234 1.02457 0.995386 -1.00068 
SUSD4 0.000248 2.30549 4.88E-06 2.56619 0.000623 1.6863 
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TACC1 0.004137 1.86312 0.003657 1.56662 0.021833 1.38121 
TAGLN2 0.000244 -2.16119 2.29E-05 -2.06975 7.57E-05 -1.87948 
TBX15 0.000193 -3.38674 3.40E-05 -2.90692 0.10777 -1.30532 
TIMP1 0.006923 -2.1708 0.001326 -2.03968 0.006492 -1.74069 
TMEM151A 0.004204 -2.4674 0.591743 -1.10075 0.448317 -1.14652 
TNK2 0.000426 -2.41461 0.00012 -2.08248 0.060092 -1.29185 
TOP1 0.005781 1.91729 0.484021 1.10046 0.765547 1.04119 
TSPAN18 6.39E-05 -2.60472 0.000627 -1.65728 0.00032 -1.73824 
UCK2 0.000347 -1.53989 0.084826 -1.11645 0.303237 -1.0645 
USP24 0.000406 -2.14232 0.00021 -1.79903 0.031117 -1.29697 
VAT1 0.009979 -1.62168 0.01592 -1.36663 0.109658 -1.20842 
VRK2 0.002518 -1.60763 0.001685 -1.42879 0.07409 -1.18219 
WHSC1L1 0.006263 1.58344 0.886824 -1.01386 0.517417 1.06532 
WNT5B 0.003831 -1.58016 0.002752 -1.4064 0.096571 -1.17178 
YDJC 0.009553 -2.04785 0.000127 -2.6014 0.045681 -1.43587 
ZCCHC11 0.004173 1.96732 0.86859 -1.02225 0.358543 1.13289 
 
3.6 JNP has subtle effect on genotoxic stress-induced apoptosis 
JNP has been established to be essential for c-JUN function in neurons in 
response to excitotoxic stimuli (Behrens et al., 1999). Nevertheless, our data 
so far suggested that JNP has only minor effect on c-JUN function in MEFs 
both under basal and genotoxic stressed conditions. To further confirm these 
results, we treated the c-Jun+/+ and c-JunAA/AA MEFs with two different doses 
of UV or CDDP for 24 hours to induce cell death and determined the extent of 






Figure 15. JNP has subtle effect on genotoxic stress-induced apoptosis 
MEFs were exposed to 40 J/m2 and 80 J/m2 of UV (top) or 15 µM and 30 µM of 
CDDP (bottom). The percentage of viable cells were determined by Annexin V and 
PI staining 24 hours post treatment. Sibling MEFs from the c-JunAA/+ mice intercross 
were used: c-Jun+/+ (green), n=6; c-JunAA/AA (red), n=7. Experiments were done in 
duplicates, data represents mean+SD. Statistics done by 2-way ANOVA, *P<0.05, 
**P<0.01. 
 
Treatment with either genotoxic stress led to a decrease in the number of 
viable cells in both c-Jun+/+ and c-JunAA/AA MEFs (Figure 15). We observed a 
small but statistically significant difference in cellular survival between the c-
Jun+/+ and c-JunAA/AA cells in response to CDDP treatment (percentage of 
viable c-Jun+/+ versus c-JunAA/AA cells at 15 μM CDDP: 78.6 versus 85.8 
[p<0.05]; percentage of viable cells at 30 μM CDDP: 35.5 versus 45.0 
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[p<0.01]). However, cellular survival between UV-treated c-Jun+/+ and c-
JunAA/AA MEFs was similar with no significance difference (percentage of 
viable c-Jun+/+ versus c-JunAA/AA cells at 40 J/m2 of UV: 70.9 versus 75.6 
[p>0.05]; percentage of viable cells at 80 J/m2 of UV: 51.6 versus 54.4 
[p>0.05]). These data indicated that JNP has subtle effect on c-JUN function 
in regulating genotoxic stress-induced apoptosis in MEFs. 
Thus, consistent with our previous findings that JNP is required only for a 
small subset of c-JUN target genes transcription, these results pieced together 
supported that JNP has limited effect in c-JUN function in MEFs even during 
exposure to genotoxic stresses. 
3.7 Stress-regulated c-JUN target genes 
Having identified genome-wide c-JUN-dependent genes at basal as well as 
under stressed conditions, we were interested in dividing and characterizing 
these genes into different groups based on their expression changes in 
response to stresses. As c-JUN is one of the immediate early responding 
proteins to a plethora of stresses (Mechta-Grigoriou et al., 2001, Vogt, 2001), 
this analysis could be an initial step to provide clues in how c-JUN behaves in 
response to different stresses. 
We converged the gene lists encompassing c-JUN-dependent genes under 
untreated (basal) or UV/CDDP treated (stressed) conditions respectively and 
identified genes that were common or unique among specific conditions. As 
illustrated in Figure 16A, many genes were initially expressed differently 
between c-Jun+/+ and c-Jun-/-  MEFs at basal level, however their expression 
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differences were lost/compensated after stress (Group 1). In addition, a large 
number of genes were regulated by c-JUN at both basal and stressed 
conditions; they are thus constitutive c-JUN targets regardless of the stress 
status (Group 2). Moreover, a substantial number of genes did not exhibit 
expression differences between c-Jun+/+ and c-Jun-/- MEFs at basal level and 
began to show expression differences upon stress; therefore these genes are 
the stress-induced c-JUN-dependent genes (Group 3). The numbers of genes 
in each individual groups regulated by UV or CDDP respectively are indicated 





Figure 16. Stress-regulated c-JUN-dependent genes 
(A) Venn Diagram illustrating the different grouping of c-JUN-dependent genes in 
response to either with stress or without stress or both. (B) Number of genes in each 
group at basal level and at stressed level with UV or CDDP respectively. 
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Many c-JUN target genes and their physiological roles have been reported by 
other groups before. These genes include Tcf4 (Tcf7l2), Cd44 and Lgr5, which 
have been shown to participate in the intestinal homeostasis and tumorigenesis 
(Nateri et al., 2005, Sancho et al., 2009, Aguilera et al., 2011). We have also 
identified these three genes as c-JUN-dependent genes but not JNP-dependent 
genes. Our results indicate that Lgr5 is a constitutive c-JUN dependent gene, 
while Cd44 and Tcf4 are stress-induced c-JUN dependent genes. Cd44 was 
induced by both UV and CDDP whereas Tcf4 was only induced by CDDP but 
no UV (Table 14).  
 
Table 14. Expression of representative known c-JUN target genes 
Gene 
Symbol 
Whole genome expression array (c-Jun-/- vs. c-Jun+/+) 
Untreated UV treated CDDP treated 
p-value FC p-value FC p-value FC 
Lgr5 1.60E-12 23.2618 6.05E-14 14.1647 9.08E-14 13.3876 
CD44 0.000375 -1.95634 1.50E-08 -2.75097 5.55E-08 -2.54092 
Tcf4 0.049251 1.54561 0.016555 1.46915 4.22E-05 2.15271 
 
To gain further insights into the cellular and molecular functions of the genes 
in each individual group, we performed gene ontology analysis by IPA 
software. IPA categorizes gene functions according to scientific publications 
and can rank the cellular and molecular functions based on the number of 
genes enriched in each function and their relative expression values. The top 
enriched cellular and molecular functions of UV and CDDP-regulated genes 






Figure 17. Top c-JUN-regulated molecular and cellular functions suggested by 
IPA 
Different groups of UV-regulated (A) and CDDP-regulated (B) c-JUN-dependent 
genes were imported to IPA software for gene ontology analysis. Top molecular and 
cellular functions calculated by IPA are indicated. X axis represents the -log(p-value), 
hence the longer the bar, the smaller the p-value (more significant).  
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Interestingly, the group 1 genes which were only differentially expressed at 
basal level did not show prominent enrichment in any particular functions; 
whereas group 2 and 3 genes which were differentially expressed at stressed 
conditions exhibited obvious functional enrichment. Apparently, the top five 
cellular and molecular functions in both UV and CDDP-regulated genes are 
'Cellular Movement', 'Cell-To-Cell Signaling and Interaction', 'Cellular 
Function and Maintenance', 'Cellular Development' and 'Cellular Growth and 
Proliferation'. These data suggest that cells respond similarly to both 
genotoxic stresses and implicated c-JUN's role in cellular interaction, 
migration, general maintenance and development. 
3.8 Potential biological pathways regulated by c-JUN  
We also grossly analyzed the differentially expressed genes between c-Jun-/- 
and c-Jun+/+ MEFs at basal, UV and CDDP-treated conditions individually to 
explore for potential biological processes/pathways that are most deregulated 
in the absence of c-JUN. Analysis by IPA uncovered many affected canonical 
pathways and the top five canonical pathways with most significant changes 
in gene expressions are shown in Figure 18. Among them, IL-10 signaling, 
complement system and hepatic fibrosis/HSC activation pathways have been 
consistently found to be affected in untreated as well as in UV/CDDP-treated 
conditions.   
IL-10 is an anti-inflammatory cytokine that functions at different stages of  
immune response in order to limit the exaggerated or excessive response to 
protect the host (Saraiva et al., 2010). Moreover, measurement of the serum 
cytokine levels in between the healthy and NAFLD patients has revealed a 
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characteristic significant increase of TNF-α along with decreasing of IL-10 in 
accordance with the severity of NAFLD (Zahran et al., 2013, Paredes-
Turrubiarte et al., 2015). Previous studies have proposed a role for c-JUN in 
regulating IL-10 expression in certain immune cell types (Jones et al., 2005, 
Wang et al., 2005), suggesting that c-JUN may be able to modulate the IL-10 




Figure 18. Top c-JUN-regulated canonical pathways suggested by IPA 
Basal and UV/CDDP regulated c-JUN-dependent genes were uploaded to IPA for 
canonical pathway analysis. X axis shows the percentage of the molecules affected in 
the indicated pathway: the open bar indicates the total number of molecules in the 
indicated pathway, while the colored bar indicates the affected molecules (red, 
upregulated in c-Jun-/- cells; green, downregulatd in c-Jun-/- cells). Significance is 
shown by -log(p-value) in orange dots, i.e. higher -log(p-value) indicates more 
significance. 
 
While the association between c-JUN and IL-10 signaling is known, two 
pathways with possible novel association with c-JUN have been uncovered - 
the complement system and hepatic fibrosis/HSC activation pathway. 
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 The complement system is part of the immune system consisting of numerous 
serum proteins as well as many soluble or membrane-bound receptors. It 
functions in recognizing an array of molecules such as pathogens to initiate 
inflammatory responses for host defense (Markiewski et al., 2007). The C1q 
complex is the first component of the classical complement pathway and is 
composed of 18 polypeptide chains of three subunits (6 C1qa, 6 C1qb and 6 
C1qc) (Nayak et al., 2012). C1q has been found to play an important role in 
the clearance of apoptotic cells in the situation of overwhelming apoptosis or 
impaired phagocytosis (Trouw et al., 2008). Interestingly, we found that 
expressions of all the three subunits were strongly reduced in c-Jun-/- MEFs 
(Table 11), suggesting that loss of c-JUN may affect the clearance of apoptotic 
cells during acute or chronic tissue damage. 
Hepatic fibrosis usually results from chronic liver diseases with an 
inflammatory microenvironment while NASH is one of its main risk factor  
(Bataller et al., 2005). HSC, as the most fibrogenic cell type, can be potently 
activated by signals (e.g. ROS and pro-inflammatory cytokines) emitted from 
dying/apoptotic hepatocytes and various type of activated immune cells 
(Friedman, 2008a). c-JUN has been found to promote hepatocyte and 
hematopoietic cell survival in various liver pathological conditions (Eferl et 
al., 1999, Hasselblatt et al., 2007, Fuest et al., 2012), suggesting that c-JUN 
may be involved in HSC activation and hepatic fibrosis development. 
Taken together, these potential c-JUN-regulated biological 
processes/pathways suggest some potential functions of c-JUN in regulating 
















c-JUN is widely expressed in a variety of tissues and it plays a pivotal role in 
liver physiology, especially in embryonic liver development, adult liver 
regeneration and tumorigenesis. However its role in liver fibrosis has not been 
defined as yet (Jochum et al., 2001, Eferl et al., 2003b). Our results from the 
canonical pathway analysis on genome-wide c-JUN-dependent genes suggest 
that c-JUN is involved in HSC activation and hepatic fibrosis pathway under 
normal physiological status. Interestingly, this pathway appeared as the top 
most affected pathway during stressed conditions, highlighting the association 
of c-JUN with HSC activation and hepatic fibrosis. It is therefore conceivable 
that c-JUN has a potential role in liver fibrosis development. Furthermore, 
JNK/c-JUN signaling has been implicated in the progression of NASH, a high 
risk factor associated with liver fibrosis (Seki et al., 2012). JNK signaling has 
also been demonstrated to modulate HSC activation and liver fibrogenesis, 
while both total c-JUN and N-terminal phosphorylated c-JUN have been 
found to be strongly augmented during hepatic fibrogenesis (Kluwe et al., 
2010, Zhao et al., 2014). A recent transcriptome-wide gene expression 
analysis on NASH mice induced by a high fat and cholesterol diet further 
proposed that c-JUN is the central protein connecting many other deregulated 
proteins to facilitate the development of NASH (Dorn et al., 2014).  
4.2 Increased baseline HSC activation in c-Jun-/- embryos  
Since HSC is the major fibrogenic cell type and its activation and 
transdifferentiation into myofibroblast-like cell is the key step in hepatic 






Figure 19. Increased baseline HSC activation in c-Jun-/- embryos 
(A, B) IHC staining for αSMA (A) and Desmin (B) in representative E13.5 c-Jun+/+ 
(left) and c-Jun-/- (right) embryos. (C) Quantitative αSMA (left) and Desmin (right) 
IHC data from all embryos (n≥4 per genotype). Data represents mean+SD, **P<0.01. 




caused extensive fetal liver apoptosis, would activate the HSCs in embryos. It 
has been reported that c-Jun-/- fetuses began to show liver morphological 
abnormalities at E13.0 and the very low fetal liver c-JUN expression also 
increased about three-fold at E13.5; suggesting that c-JUN gains significance 
in the liver around E13.5 (Eferl et al., 1999). We therefore chose E13.5 c-
Jun+/+ and c-Jun-/- embryos to investigate their baseline HSC status.  
Two classical HSC markers, αSMA and desmin, were assessed by 
immunohistochemistry (IHC). As expected, the proportion of αSMA-positive 
and desmin-positive cells, representing activated HSCs, increased 
dramatically in c-Jun-/- embryos in comparison to c-Jun+/+ embryos (Figure 
19). These data strongly indicate that loss of c-JUN resulted in HSC activation 
and accumulation; impling that c-Jun-/- mice may exhibit spontaneous 
congenital fibrosis. Thereby, we hypothesized that c-JUN is involved in 
hepatic fibrosis development. 
4.3 Inactivation of c-JUN in HSCs 
To investigate the role of c-JUN in adult liver fibrosis, we first conditionally 
deleted c-JUN in adult murine HSCs. Kinoshita et al. have demonstrated that 
the Col1a2 promoter is an effective and specific promoter to drive the Cre 
recombinase expression in activated HSCs (Kinoshita et al., 2007). We 
therefore employed Col-CreER (Col-CreERtg) transgenic mice, in which the 
Cre recombinase is fused to a modified estrogen receptor (ER) ligand binding 
domain and the resulting CreER fusion protein is controlled by the Col1a2 
promoter (Zheng et al., 2002). The Col-CreERtg transgenic mice were then 
sequentially crossed with c-Junf/f mice to obtain c-Junf/f;Col-CreERtg and c-
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Junf/f;Col-CreERntg (equivalent to and here on designated as c-Junf/f) mice 
(Table 15). As 4-hydroxytamoxifen, a metabolite of the tamoxifen, is required 
to activate the CreER fusion protein, both c-Junf/f;Col-CreERtg and c-Junf/f 
mice were administrated with equal doses of tamoxifen to avoid confounding 
phenotypes. 
 
Table 15. Sequential crossing of Col-CreERtg transgenic mice with c-Junf/f mice 
illustrated by Punnett squares 
 
  Col-CreERtg 
  c-Jun+;Col-CreERtg c-Jun+;Col-CreERntg 
c-Junf/f 
c-Junf c-Junf/+;Col-CreERtg c-Junf/+;Col-CreERntg 
c-Junf c-Junf/+;Col-CreERtg c-Junf/+;Col-CreERntg 
    





























    
  c-Junf/f;Col-CreERtg 
  c-Junf;Col-CreERtg c-Junf;Col-CreERntg 
c-Junf/f 
c-Junf c-Junf/f;Col-CreERtg c-Junf/f;Col-CreERntg 





Figure 20. c-JUN inactivation in HSCs 
Both c-Junf/f and c-Junf/f;Col-CreERtg mice were administrated with tamoxifen. In 
addition, mice were treated with CCl4 (n=8 for each genotype) to induce c-JUN 
expression; or with oil (n=5 for each genotypes) as vehicle control. Whole liver 
fractions were used to examine c-JUN expression by qRT-PCR. Experiments were 
done in duplicates, data represents mean+SD. Statistics done by t-test, *P<0.05. 
 
c-JUN inactivation was assessed by whole liver qRT-PCR (Figure 20). 
Interestingly, c-JUN level was markedly augmented in both c-Junf/f and c-
Junf/f;Col-CreERtg mice following CCl4 treatment as compared to oil 
treatment, indicating that hepatic c-JUN expression can be induced in 
response to liver damage. However, oil-treated c-Junf/f and c-Junf/f;Col-
CreERtg mice exhibited almost equivalent levels of c-JUN expression, 
suggesting inadequate c-JUN inactivation in oil-treated mice probably due to 
the Col1a2 promoter which could only modestly drive Cre expression in 
quiescent HSCs (Kinoshita et al., 2007). Nevertheless, liver damage can 
activate HSC (Bataller et al., 2005) and the Col1a2 promoter can then 
competently drive Cre expression in activated HSCs (Kinoshita et al., 2007). 
Hence, we observed significantly less c-JUN induction in c-Junf/f;Col-CreERtg 
mice than in c-Junf/f mice by CCl4. This indicates a successful c-JUN 
inactivation in activated HSCs. Notably, HSCs only comprise approximately 
10% of the total liver resident cells (Geerts, 2001). The efficient induction of 
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c-JUN expression by CCl4 in c-Junf/f;Col-CreERtg mice can therefore be 
attributed to other liver cell types which harbor the intact c-Jun gene. 
4.4 Loss of c-JUN in HSCs aggravates fibrosis 
We next investigated the consequences of c-JUN inactivation in HSCs on 
fibrosis progression in a CCl4 intoxication model. CCl4 is a classical 
hepatotoxicant that causes pericentral injury. Its metabolism by hepatocyte 
cytochrome P450 2E1 generates highly reactive free radical metabolites which 
results in lipid peroxidation and hepatocellular membrane disruption 
(Manibusan et al., 2007). Therefore, it has been widely used experimentally to 





Figure 21. Detailed injection and harvesting scheme for c-Junf/f;Col-CreERtg and 
c-Junf/f mice 
c-Junf/f;Col-CreERtg and c-Junf/f;Col-CreERntg (c-Junf/f) mice were injected twice per 
week with the indicated dosage of oil (yellow) or CCl4 (red) for 4 weeks, 6 weeks or 
8 weeks respectively. In addition, tamoxifen (blue) was also fed to all the 
experimental mice along with the oil or CCl4 treatment. All mice were harvested 48-
72 hour after the last injection. 
 
We subjected equal numbers of six-week-old male and female c-Junf/f;Col-
CreERtg and c-Junf/f mice to 4, 6 and 8 weeks of treatment with either CCl4 (1 
μl/gbw) or olive oil (vehicle control) (Figure 21). 8-10 mice were collected per 
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genotype, treatment and time period. All liver specimens collected in this 
experiment were then analyzed by Sirius Red staining to assess the fibrosis 
and by H&E staining to evaluate the overall liver morphology. Sirius Red can 
directly stain the collagen proteins in the ECM and has long been considered 
as the „gold standard‟ for assessing liver fibrosis (Bataller et al., 2005). The 
degree of fibrosis was determined by quantitative measurement of the 
percentage of Sirius Red positive regions over the whole liver by Metamorph 
software because it appeared more accurate than various semi-quantitative 
scoring systems.  
Light microscopy images of Sirius Red and H&E staining from representative 
liver specimens are shown in Figure 22 A to C. Sirius Red staining revealed 
that all the oil-treated mice, regardless of their genotypes, did not form any 
fibrotic septa; whereas all mice with time course CCl4 treatment showed 
extensive formation of fibrotic septa. Quantification of the Sirius Red positive 
area (fibrotic area) over the whole liver (Figure 22D) revealed that 
approximately 3% of the liver area appeared Sirius Red positive in 4 weeks 
CCl4-treated c-Junf/f and c-Junf/f;Col-CreERtg mice, which is approximately a 
four-fold increase over the oil-treated controls. No major difference on the 
degree of fibrosis was detected between these two genotypes. Interestingly, 
with prolonged CCl4 treatment, we began to observe significantly more 
fibrosis developing in c-Junf/f;Col-CreERtg mice. In the 6 weeks treatment 
group, the average fibrotic area in c-Junf/f;Col-CreERtg mouse livers was 
approximately 30% larger than in c-Junf/f mouse livers. As shown in Figure 22 
B and D, the percentage of Sirius Red positive regions was 5.00% in c-













Figure 22. Loss of c-JUN in HSCs aggravates fibrosis 
c-Junf/f (left) and c-Junf/f;Col-CreERtg (right) mice were treated with oil or CCl4 for 4 
weeks (A), 6 weeks (B) and 8  weeks (C) respectively. Number of mice: n≥5 in Oil-
treated group per time period; n≥8 in CCl4-treated group per time period. (A to C) 
Sirius Red (top panels) and H&E (bottom panels) staining of liver sections from 
representative mice (10X magnification). (D) Quantification of fibrosis based on 
Sirius Red staining by 20 randomly chosen fields (10X) from four individual liver 
lobes per mouse. Data represents mean+SD. Statistics done by 2-way ANOVA, 
**p<0.01, ***P<0.001. 
 
difference in fibrogenesis was even more pronounced in the 8 weeks treatment 
group. The c-Junf/f;Col-CreERtg mouse livers contain  7.80% fibrotic region 
whereas the c-Junf/f mouse livers contain only 4.80% fibrotic region in 
average; demonstrating about 60% more hepatic fibrosis developed in c-
Junf/f;Col-CreERtg mice over the control genotype. Moreover, the fibrotic 
scars formed in c-Junf/f;Col-CreERtg mice at this stage were much broader 
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(Figure 22C), suggesting an increase in matrix stiffness compared to the 
control genotype. These data clearly demonstrated that the loss of c-JUN in 
HSCs strongly promoted fibrosis progression; indicating that c-JUN functions 
in activated HSCs to limit fibrosis development during chronic liver injury.  
4.5 c-JUN deletion in HSCs potentiates HSC activation 
As the fibrogenic process is consecutive to HSC activation, we next examined 
whether c-JUN deletion in HSC could affect its activation. Hepatic expression 
of three classical activated HSC markers, αSMA, Desmin and Vimentin, were 
assessed by whole liver qRT-PCR (Figure 23A). CCl4 potently stimulated the 
expression of all three markers in both c-Junf/f and c-Junf/f;Col-CreERtg mice 
as compared to oil-treated mice. Remarkably, as expected, c-Junf/f;Col-
CreERtg mice showed significantly higher levels of HSC markers induction 
than c-Junf/f mice, indicating a greater extent of HSC activation in these mice.  
Activated HSCs can produce large amount of fibrillar ECM proteins. The 
most-studied and increased ECM protein during fibrogenesis is type I collagen 
(Bataller et al., 2005, Tsukada et al., 2006, Friedman, 2008b). Type I collagen 
is a heterotrimeric protein composing of two α1 and one α2 chains encoded by 
Col1a1 and Col1a2 genes respectively. Its increase is directly reflected by an 
increase in Col1a1 and Col1a2 mRNA levels (Tsukada et al., 2006). Thus, we 
analyzed hepatic Col1a1 and Col1a2 expressions (Figure 23B) and found 
substantial upregulation of both genes (more than 20-fold increase of Col1a1 
expression and more than 10-fold increase of Col1a2 expression) after 
repetitive exposure to CCl4 as compared to oil which act as control. Strikingly, 





Figure 23. c-JUN deletion in HSCs potentiates HSC activation 
Whole liver RNA extracts from 8 weeks oil (n=5 per genotype) or CCl4 (n=8 per 
genotype) treated c-Junf/f and c-Junf/f;Col-CreERtg mice were used to determine 
activated HSC markers and fibrogenic genes expression by qRT-PCR (normalized 
against Gapdh). (A) Activated HSC markers α-SMA, Desmin and Vimentin mRNA 
As levels. (B) Type I Collagen mRNA levels. (C) TGF-β1 mRNA level. Experiments 
were done in duplicates, data represents mean+SD. Statistics done by 2-way 





times higher in CCl4-treated c-Junf/f;Col-CreERtg mice than in CCl4-treated c-
Junf/f mice. This data is consistent with the previous Sirius Red staining results 
showing that c-Junf/f;Col-CreERtg mouse livers contain significantly larger 
fibrotic regions. This further corroborates a stronger HSC profibrogenic 
activity in these mice. 
Another key fibrogenic marker is TGF-β1 (encoded by Tgfb1). TGF-β1 is the 
most potent fibrogenic cytokine expressed in nonparenchymal liver cells 
mainly HSCs and Kupffer cells (De Bleser et al., 1997, Bataller et al., 2005). 
In HSCs, TGF-β1 function to stimulate their activation and fibrogenesis (e.g. 
promotes collagen synthesis and inhibits collagen degradation) (Bataller et al., 
2005). As shown in Figure 23C, hepatic TGF-β1 expression seemed to be 
comparable between c-Junf/f;Col-CreERtg and c-Junf/f mice. However, we used 
whole liver fractions to evaluate TGF-β1 expression while hepatocytes being 
the most abundant cell type in the liver do not express it (De Bleser et al., 
1997). Therefore, there could be a dilution effect and thus purification of 
HSCs is needed for an accurate evaluation of TGF-β1 expression in these 
mice. 
Taken together, these data strongly demonstrated that c-Junf/f;Col-CreERtg 
mice, which harbor genetic inactivation of c-JUN in activated HSCs, 
contained more activated HSCs and maintained greater fibrogenic activity. 
4.6 Inactivation of c-JUN in hepatocytes and hematopoietic cells 
Liver is a multicellular organ where cell-to-cell signaling and interaction 
orchestrate to regulate its normal function as well as injury responses. Given 
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the complexity of hepatic fibrosis and the involvement of different liver cell 
types, we next ablated c-Jun in other liver cell types without affecting it in 
HSCs to obtain a more complete picture of how c-JUN regulates hepatic 
fibrosis. We crossed c-Junf/f mice with Mx-Cretg transgenic mice, which carry 
the Cre transgene under the control of an interferon-inducible Mx1 promoter 
(Kuhn et al., 1995), in an identical way as the sequential breeding of c-Junf/f 
mice and Col-CreERtg transgenic mice. The progeny littermate c-Junf/f;Mx-
Cretg and c-Junf/f;Mx-Crentg (equivalent to and here on designated as c-Junf/f) 
mice were used for subsequent experiments. As Poly I/C is required to induce 
the interferon production in order to activate Cre transgene expression, all 
experimental mice were administrated with Poly I/C to avoid confounding 
phenotypes. The expressed Cre recombinase can robustly delete c-Jun in both 
hepatocytes and hematopoietic cells in the liver (Maeda et al., 2005). As 
shown in Figure 24, c-JUN expression was significantly impaired in both oil 




Figure 24. c-JUN inactivation in hepatocytes and hematopoietic cells 
Both c-Junf/f and c-Junf/f;Mx-Cretg mice were administrated with Poly I/C. In addition, 
mice (n=8 for each genotype) were treated with CCl4 to induce c-JUN expression; or 
with oil (n≥5 for each genotype) as vehicle control. Whole liver fractions were used 
to examine c-JUN expression by qRT-PCR. Experiments were done in duplicates, 
data represents mean+SD. Statistics done by t-test, **P<0.01, ***P<0.001. 
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4.7 Loss of c-JUN in hepatocytes and hematopoietic cells ameliorates 
fibrosis 
We went on to investigate the effect of c-JUN in hepatocytes and 
hematopoietic cells in hepatic fibrosis. We again subjected six-week-old c-
Junf/f and c-Junf/f;Mx-Cretg mice of balanced genders to the same dose and 
time periods of oil or CCl4 treatment. Of note, sufficient doses of poly I/C 
were administrated prior to oil and CCl4 treatment to ensure efficient c-JUN 






Figure 25. Detailed injection and harvesting scheme for c-Junf/f;Mx-Cretg and c-
Junf/f mice 
c-Junf/f;Mx-Cretg and c-Junf/f;Mx-Crentg (c-Junf/f) mice were injected twice per week 
with the indicated dosage of oil (yellow) or CCl4 (red) for 4 weeks, 6 weeks or 8 
weeks respectively. In addition, indicated dosage of Poly I/C (green) was injected to 
all the experimental mice before the first week of the oil or CCl4 treatment. All mice 
were then harvested at 48 to 72 hour after the last injection. 
 
 
Liver fibrosis and overall morphology were also evaluated by Sirius Red and 
H&E staining respectively; representative histology pictures are depicted in 
Figure 26. As expected, the protocol produced 100% fibrosis in all CCl4-
treated mice. Surprisingly, we observed small but significantly less fibrosis 













Figure 26. Loss of c-JUN in hepatocytes and hematopoietic cells ameliorates 
fibrosis 
c-Junf/f (left) and c-Junf/f;Mx-Cretg (right) mice were treated with oil or CCl4 for 4 
weeks (A), 6 weeks (B) and 8  weeks (C) respectively. Number of mice: n≥7 in oil-
treated group per time period; n≥8 in CCl4-treated group per time period. (A to C) 
Sirius Red (top panels) and H&E (bottom panels) staining of liver sections from 
representative mice (10X magnification). (D) Quantification of fibrosis based on 
Sirius Red staining by 20 randomly chosen fields (10X) from four individual liver 
lobes per mouse. Data represents mean+SD. Statistics done by 2-way ANOVA, 
*P<0.5, **p<0.01, ***P<0.001. 
 
have analyzed (c-Junf/f;Mx-Cretg versus c-Junf/f; percentage of Sirius Red 
positive regions upon 4 weeks CCl4 treatment: 2.63 versus 3.11 [p<0.001]; 
percentage of Sirius Red positive regions upon 6 weeks CCl4 treatment: 2.66 
versus 3.34 [p<0.05]; percentage of Sirius Red positive regions upon 8 weeks 
CCl4 treatment: 4.02 versus 4.74 [p<0.01]). These data demonstrated a 
persistent 15~20% less fibrotic areas in CCl4-treated c-Junf/f;Mx-Cretg over the 
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control c-Junf/f mice; indicating that ablation of c-JUN in hepatocytes and 
hematopoietic cells limits fibrosis progression. Intriguingly, these data 
revealed a completely opposite role of c-JUN in hepatocytes and 
hematopoietic cells as compared to in HSCs during the progression of fibrosis. 
4.8 c-JUN deletion in hepatocytes and hematopoietic cells attenuates HSC 
activation 
As paracrine signaling plays an important role in stimulating and maintaining 
HSC activation, we next sought to investigate whether inactivation of c-JUN 
in hepatocytes and hematopoietic cells would affect HSC activation during 
liver injury. By comparing the hepatic expression of αSMA, Desmin and 
Vimentin genes between c-Junf/f and c-Junf/f;Mx-Cretg mice, we again 
observed significant induction of all three HSC activation markers in both 
genotypes generated by CCl4 treatment (Figure 27A), indicating that the 
inactivation of c-JUN in hepatocytes and hematopoietic cells does not impair 
HSC activation in response to liver injury. However, we noticed that the 
extent of the inductions of these HSC activation markers was significantly 
reduced in c-Junf/f;Mx-Cretg mice (Figure 27A). These results revealed that 
inactivating c-JUN in hepatocytes and hematopoietic cells, but not in HSCs, 
can result in lower HSC activation; highlighting the importance of paracrine 
signaling in regulating HSC fate.  
Moreover, analysis of the hepatic Col1a1 and Col1a2 expressions revealed 
that the overall increase of type I collagen synthesis (both Col1a1 and Col1a2 
mRNA levels) during chronic CCl4-induced fibrogenesis was approximately 





Figure 27. c-JUN deletion in hepatocytes and hematopoietic cells attenuates HSC 
activation 
Whole liver RNA extracts from 4 weeks oil (n≥5 per genotype) or CCl4 (n=8 per 
genotype) treated c-Junf/f and c-Junf/f;Mx-Cretg mice were used to determine activated 
HSC markers and fibrogenic genes expression by qRT-PCR (normalized against 
Gapdh). (A) Activated HSC markers α-SMA, Desmin and Vimentin mRNA levels. 
(B) Type I Collagen mRNA levels. (C) TGF-β1 mRNA level. Experiments were 
done in duplicates, data represents mean+SD. Statistics done by 2-way ANOVA, 




This data is consistent with the Sirius Red quantification results that c-
Junf/f;Mx-Cretg livers contain significantly less collagen deposition, suggesting 
a reduced HSC activity in these mice. 
Moreover, hepatic TGF-β1 expression was similar between c-Junf/f;Mx-Cretg 
and c-Junf/f  mice (Figure 27C). Considering the fact that TGF-β1 is mainly 
expressed in the nonparenchymal cells (De Bleser et al., 1997), cell type-
specific expression of TGF-β1 needs to be defined to better understand the 
hepatic microenvironment. 
These data together clearly manifested that inactivating c-JUN in hepatocytes 
and hematopoietic cells but not in HSCs led to reduced HSC activation and 
fibrogenesis by an unknown mechanism. This probably contributed to reduced 
fibrosis progression in c-Junf/f;Mx-Cretg mice. 
4.9 Increased expression of Hh pathway components in c-JUN-deficient 
cells and mice  
The fact that activated HSCs tend to accumulate in c-Jun-/- embryos as well as 
in mice with HSC-specific c-JUN deletion (c-Junf/f;Col-CreERtg), but not in 
mice with hepatocytes and hematopoietic cells-specific c-JUN deletion  (c-
Junf/f;Mx-Cretg), suggests a c-JUN-mediated cell-autonomous mechanism for 
HSC to regulate its own activation.  
Studies have reported active Hh signaling in HSCs but not in liver 
parenchymal cells as HSCs are Hh-responsive cells while hepatocytes are not. 
HSC can produce biologically active Hh ligands. These ligands in turn 
activate Hh signaling in HSC via autocrine thereby promote its activation and 
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viability (Sicklick et al., 2005, Yang et al., 2008). Inhibition of active Hh 
signaling by pharmacologic inhibitor cyclopamine considerably reduced HSC 
activation both in vitro and in vivo (Sicklick et al., 2005). Moreover, Hh 
ligands can mediate cytokine (such as PDGF-BB)-induced HSC proliferation. 
Inhibition of active Hh signaling by pharmacologic inhibitors or neutralizing 
antibodies drastically blocked the mitogenic effect of cytokines to HSC (Yang 
et al., 2008).  
Interestingly, we have identified Gli2 as a c-JUN-dependent gene from our 
whole genome expression array data in primary MEFs. Gli2 is a Hh activated 
transcription factor whose function is to transactivate Hh-target gene 
expression therefore serving as a marker for active Hh signaling (Grzelak et 
al., 2015). Hence, we validated Gli2 expression by qRT-PCR and detected 
approximately two-fold higher Gli2 level in c-JUN-deficient MEFs (Figure 
28). This suggests that c-JUN can suppress Gli2 expression and prompted us 
to hypothesize that c-JUN may modulate HSC activation by interfering with 




Figure 28. c-JUN downregulates Gli2 expression 
c-Jun+/+ and c-Jun-/- MEFs (n≥4 per genotype) were used for qRT-PCR analysis of 






Figure 29. Increased expression of Hh pathway components in c-Jun-/- embryos 
(A, B) IHC staining for Ihh (A) and Gli2 (B) in representative E13.5 c-Jun+/+ (left) 
and c-Jun-/- (right) embryos. (C) Quantitative Ihh (left) and Gli2 (right) IHC data 
from all embryos (n≥4 per genotype). Data represents mean+SD, **P<0.01. Data in 





We thus investigated whether Hh signaling was generally more active in c-
Jun-/- background by comparing the expression of Hh pathway components in   
c-Jun+/+ and c-Jun-/- embryos. As expected, IHC staining revealed vastly 
higher amount of Ihh, a Hh ligand, as well as Gli2 transcription factor in c-
Jun-/- embryos than in c-Jun+/+ embryos (Figure 29). These data indicate that 
Hh signaling is greatly augmented in the absence of c-JUN and strongly 
suggest a possible mechanism in modulating HSC activation through the 

















5.1 Identification and characterization of c-JUN-regulated genes  
c-JUN is the central molecule of the AP-1 transcription factor complex and 
acts as a convergence point of many signaling cascades to control 
corresponding target gene transcription in different cellular programs 
(Shaulian et al., 2001, Shaulian et al., 2002, Eferl et al., 2003b). Historically, 
JNK-mediated JNP was thought to be essential for c-JUN function. However, 
since c-JunAA/AA mice were viable and fertile with no major defects, this 
conventional thought has been changed (Behrens et al., 1999). Till date, 
mounting evidence have reported that JNP is important but not absolutely 
required for multiple aspects of c-JUN functions including cell proliferation, 
apoptosis and transformation (Behrens et al., 1999, Behrens et al., 2001, 
Besirli et al., 2005). Hence, it is now well accepted that JNP only partially 
contributes to c-JUN activity. Researchers have therefore tried different 
attempts to investigate how c-JUN functions in JNP-dependent and -
independent manner. Behrens et al. have embarked on this subject by 
screening proteins from a brain library that interact differently with N-terminal 
phosphorylated and unphosphorylated forms of c-JUN in order to dissect their 
roles in different biological processes (Nateri et al., 2004). By this approach, 
they successfully identified and characterized several such proteins including 
Fbw7, TCF4, Bag1-L, RACO-1 and Mbd3 (Nateri et al., 2004, Nateri et al., 
2005, Da Costa et al., 2010, Davies et al., 2010, Aguilera et al., 2011). As c-
JUN is a transcription factor, we, on the other hand, focused on identifying 
target genes that are differentially regulated by N-terminal phosphorylated and 
unphosphorylated c-JUN. The data presented from this study demonstrate that 
globally JNP is required only for a small subset of c-JUN target gene 
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transcription. Moreover, we have also shown that JNP has subtle effect on c-
JUN functions in response to genotoxic stresses.  
5.1.1 Absence of c-JUN has a greater impact on gene expression than the 
absence of JNP 
Our main goal was to identify genes that are regulated differently by N-
terminal phosphorylated and unphosphorylated c-JUN. To elucidate this 
question, we have generated transcriptome profiles of c-Jun+/+, c-Jun-/- and c-
JunAA/AA samples prepared from both viable embryos and primary MEFs, with 
or without stresses, to seek for differentially expressed genes. 
Although we did not detect any gene showing statistically significant 
difference in expression in E11.5 embryos carrying different c-JUN 
genotypes, we have indeed successfully identified a large number of genes in 
cultured primary MEFs whose expression were significantly altered in the 
presence or absence of c-JUN (c-JUN-dependent genes). Interestingly, the 
number of c-JUN-dependent genes is doubled after UV/CDDP stimulation as 
compared to the unstimulated condition, indicating that the transcriptional 
activity of c-JUN is significantly augmented during stress. Moreover, we have 
also identified fewer genes whose expression were significantly modulated by 
JNP (JNP-dependent genes) and validated all by qRT-PCR. Surprisingly, the 
maximum gene expression difference caused by JNP (FC between c-Jun+/+ 
and c-JunAA/AA MEFs) was only about 3-fold. Whereas we detected up to 28-
fold expression difference caused by c-JUN (FC between c-Jun+/+ and c-Jun-/- 
MEFs) amongst the selected c-JUN-dependent genes validated by qRT-PCR. 
As we have detected visibly abundant N-terminal phosphorylated c-JUN 
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protein by immunoblots, especially after stress, this suggests that the presence 
of this N-terminal phosphorylated form of c-JUN does not contribute much to 
its function in transcriptional regulation, both in the number of genes and in 
the extent of gene activation/suppression. These findings provide a novel view 
on how c-JUN functions as a transcription factor: the N-terminal 
unphosphorylated c-JUN is sufficient to induce/suppress most of its target 
gene transcription, while the function of JNP in regulating transcription is 
limited to only a small subset of genes by further enhancing their 
transcription.  
5.1.2 Activities of c-JUN and JNP are insignificant at E11.5 day of embryonic 
development  
The reason for not obtaining any c-JUN and JNP-dependent genes in E11.5 
embryos is probably due to insignificant activities of c-JUN and JNP at this 
stage of embryonic development. Previous studies have already demonstrated 
that liver is the most affected organ during embryonic development in the c-
JUN null embryos. However, c-Jun-/- livers do not show deregulated 
expressions of the corresponding genes (including hepatoblast differentiation 
markers, growth regulators and known AP-1 targets) as well as morphological 
abnormalities until E12.5 (Eferl et al., 1999). While liver abnormalities cannot 
be detected, embryos at this stage already exhibit heart abnormalities, 
indicating that the E12.5 day embryos are not healthy (Eferl et al., 1999). 
Hence, E11.5 appeared as a better time point that precluded all detectable 
abnormalities in order to identify c-JUN-dependent genes under normal 
physiological condition. Moreover, JNP has no impact on c-JUN activity 
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under normal physiological condition as well. c-JunAA/AA mice do not exhibit 
any overt defects that are found in the c-Jun-/- mice (Behrens et al., 1999). 
These reports, together with our data suggest that under normal physiological 
condition, when all c-Jun+/+, c-Jun-/- and c-JunAA/AA mice are grossly normal, 
c-JUN and JNP do not cause detectable differences at both morphological and 
genomic levels.  
5.1.3 N-terminal unphosphorylated c-JUN possesses transcriptional activity 
The fact that the expression of only a minimal number of genes are affected by 
JNP suggests that the c-JUNAA protein acquires comparable transcriptional 
ability and is able to regulate c-JUN target gene transcription to a similar 
extent as c-JUNWT. This could be due to a compensatory effect by 
phosphorylation on other residues such as threonines 91/93 by JNKs (Reddy 
et al., 2013). In fact, previous reports have proposed that c-JUNAA or even c-
JUN4A (4 JNK phosphoacceptor sites, serines 63/73 and threonines 91/93, are 
mutated to alanines) protein can activate various promoters such as TRE by 
luciferase assays (Behrens et al., 1999, Davies et al., 2010). These findings in 
accordance with our data together support that N-terminal unphosphoryated c-
JUN can mediate gene transcription. 
The mechanism of how N-terminal unphosphorylated c-JUN (c-JUNAA as 
well as c-JUN4A) mediates gene transcription has been proposed to be 
through the cooperation with several newly discovered c-JUN interacting 
proteins. In recent years Behrens and his coworkers have identified many 
proteins that can interact with c-JUN with regard to the JNP status; among 
them RACO-1 and Mbd3 have been delineated to be able to interact with N-
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terminal unphosphorylated c-JUN and thereby regulate gene transcription 
(Davies et al., 2010, Aguilera et al., 2011). RACO-1 is a novel RING-domain-
containing protein widely expressed in many cell lines of different tissue 
origin. It can interact with and act as a coactivator to enhance transcriptional 
activity of both wild type and N-terminal unphosphorylated c-JUN with 
similar efficiency. Importantly, the cooperation between RACO-1 and N-
terminal unphosphorylated c-JUN is mediated by the Raf/MEK/ERK pathway 
instead of the JNK pathway, highlighting the importance of c-JUN function in 
a JNP-independent manner (Davies et al., 2010). Mbd3 is a subunit of 
nucleosome remodeling and histone deacetylation (NuRD) complex that 
mediates gene repression. Mbd3 only interacts with the N-terminal 
unphosphorylated form of c-JUN, but not with the N-terminal phosphorylated 
form of c-JUN. Therefore the N-terminal unphosphorylated c-JUN recruits the 
NuRD complex, containing Mbd3, by specifically interacting with Mbd3 and 
functions to repress its transcriptional activity. JNP, on the other hand, by 
activated JNK signaling can release the N-terminal phosphorylated c-JUN 
from this inhibitory complex (Aguilera et al., 2011).  
Collectively, previous reports together with our data strongly support that c-
JUN can regulate gene activation/repression in a JNP-independent manner. 
JNP can modulate only a small subset of c-JUN target gene transcription and 
is generally not required for most of c-JUN target gene transcription.  
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5.1.4 JNP has mild effect on MEFs proliferation and genotoxic stress-induced 
apoptosis  
Besides the limited effect of JNP in modulating c-JUN responsive gene 
transcription, we have also demonstrated that JNP exerts mild effect on c-JUN 
in regulating MEFs proliferation and genotoxic stress-induced apoptosis.  
By culturing primary MEFs in low oxygen (3% oxygen), we found that both 
c-Jun-/- and c-JunAA/AA MEFs grew appreciably with only slightly slower 
proliferation rates than c-Jun+/+ MEFs, indicating that both c-JUN and JNP 
exhibit subtle effect on MEFs proliferation. Consistent with our observation, 
the sizes of the viable c-Jun-/- and c-JunAA/AA fetuses were indistinguishable 
from the wild type fetuses (Hilberg et al., 1993, Johnson et al., 1993, Behrens 
et al., 1999), implicating that differences in c-JUN and JNP do not 
significantly affect in vivo development. However, a number of studies have 
addressed this question before and reported contrasting results. By 
maintaining cells under conventional culture condition (21% oxygen), those 
studies reported that c-Jun-/- cells exhibited severe proliferation defect with a 
premature senescence phenotype, while c-JunAA/AA cells showed partial and 
clear proliferation defect compare to wild type cells (Johnson et al., 1993, 
Behrens et al., 1999, Schreiber et al., 1999). Intriguingly, it has been 
suggested that the cellular proliferation defect is due to the hyperoxic stress 
experienced during conventional culture condition (21% oxygen), as cells in 
vivo are only exposed to a maximal of 5% oxygen (MacLaren et al., 2004). 
Thus, our culture condition, being similar to the physiological oxygen level, 
should better reflect the in vivo proliferation rates. Therefore, we believe that 
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JNP has only a mild effect on proliferation of MEFs under normal 
physiological condition.  
Similarly, JNP shows mild effect on MEFs apoptosis in response to UV and 
CDDP. We found that c-JunAA/AA MEFs were significantly and modestly more 
resistant to CDDP exposure compared to c-Jun+/+ MEFs. On the other hand, 
we detected no significant resistance of c-JunAA/AA MEFs to UV-induced 
apoptosis. This suggests that UV and CDDP trigger apoptosis by different 
mechanisms. It has been shown before that c-JunAA/AA MEFs are partially 
protected from cellular apoptosis in response to UV (Behrens et al., 1999). 
Again the difference in the observation is probably due to different cell culture 
conditions (oxygen levels). Moreover, c-Jun+/+ and c-JunAA/AA MEFs also 
exhibited similar degree of apoptosis in response to other stress such as 
alkylating agent MNNG (Behrens et al., 1999). Taken together, JNP exerts 
subtle effect on cellular apoptosis in MEFs and in a stress-dependent manner.  
5.1.5 JNP is not absolutely required for c-JUN stability 
JNK-mediated phosphorylation is an important mechanism for c-JUN 
stabilization (Karin et al., 1997). We have shown by immunoblots that both 
UV and CDDP strongly activate JNK and c-JUN. Interestingly, we note that c-
JUNAA which lacks JNP can still be stabilized by both stresses, which is 
represented by its increased steady-state levels. This observation suggests that 
there should be JNP-independent mechanism that contributes to c-JUN 
abundance, probably through increased transcription and/or other post-
translational modifications. In fact, phosphorylation at threonines 91/93 is also 
important for c-JUN turnover. For example, the E3 ligase Fbw7 that 
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specifically regulates the N-terminal phosphorylated c-JUN turnover could 
also target c-JUNAA efficiently for proteasomal degradation. However, the c-
JUN4A mutant could resist the Fbw7-mediated degradation (Nateri et al., 
2004), suggesting that phosphorylation at threonines 91/93 is also important 
for c-JUN stabilization. Therefore, in conclusion, our data shows that JNP 
exerts subtle effect but is not absolutely required for both c-JUN activity and 
stability.  
5.1.6 The significance of JNP is dependent on the cell type and stimulus  
We have demonstrated the limited involvement of JNP in c-JUN action in 
MEFs mainly in response to genotoxic stresses. Of note, the limited effect of 
JNP on c-JUN activity is not restricted to MEFs. Previous studies from other 
groups have also revealed that JNP is not required for several critical c-JUN 
functions especially in the liver. These include embryonic hepatogenesis and 
liver regeneration in response to PH (Behrens et al., 1999, Behrens et al., 
2002).  
Nevertheless, JNP is not always dispensable for c-JUN function, since the 
impact of JNP on c-JUN activity appears to depend on cell type and/or 
stimulus. JNK signaling, a mediator of JNP, plays crucial roles in multiple 
biological processes in lymphocytes and neurons. The N-terminal 
phosphorylated c-JUN thereby serves as an important effector molecule of the 
JNK signaling at least in T cells and neurons. In vitro studies have revealed 
that lack of JNP could partially protect cellular apoptosis induced by (1) anti-
CD3 antibody and TNF-α but not Fas and UV in thymocytes (Behrens et al., 
2001) and (2) trophic factor deprivation and several DNA damage agents such 
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as Ara-C and etoposide in sympathetic neurons and CGNs (Besirli et al., 
2005). Importantly, JNK-mediated phosphorylation at c-JUN threonines 91/93 
rather than serines 63/73 has been reported as the more responsive regulatory 
sites for the pro-apoptotic activity of c-JUN in CGNs (Reddy et al., 2013). 
Moreover, in vivo studies have shown that mice lacking of JNP exhibited (1) 
reduced anti-CD3 induced thymocyte apoptosis (Behrens et al., 2001) and (2) 
resistance to kainic acid but not to pentylenetetrazole induced epileptic 
seizures (Behrens et al., 1999). All these findings clearly demonstrate that JNP 
is important but not always crucial for c-JUN function even in T cells and 
neurons, highlighting that the impact of JNP is also in a stimulus-dependent 
manner. 
Furthermore, evidence regarding the significance of JNP have also been 
corroborated in transformed cells. p73 was found to cooperates preferentially 
with AP-1 dimers that are composed of c-JUN and FRA1 (Vikhanskaya et al., 
2007) or c-JUN and c-FOS (Subramanian et al., 2015) in a JNP-dependent 
manner to promote cancer cell proliferation and survival. Transcription factor 
TCF4 has been identified to preferentially interact with the N-terminal 
phosphorylated form of c-JUN, together with Wnt activated cofactor β-catenin 
to form a ternary complex to regulate intestinal tumorigenesis triggered by 
mutant APC. Importantly, the cooperation between TCF4 and phosporylated 
c-JUN only occurred in HCT116 and SW480 colon cancer cells but not in 
NIH3T3 fibroblast (Nateri et al., 2005), again emphasizing the importance of 
JNP in a cell-type specific manner. 
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Taken together, our data in line with data from other groups strongly indicate 
that the significance of JNP in c-JUN functions is both cell/tissue type and 
stimulus-dependent. In MEFs and with genotoxic stresses like UV and CDDP, 
JNP appears to have a minor effect on c-JUN function and stability. 
5.2 Role of c-JUN in hepatic fibrosis  
The liver functions as a metabolic and detoxification organ that constantly 
processes endogenous and exogenous substances to maintain the system 
homeostasis. Increased risk of hepatocellular damage occurs during 
overloading of nutrients and/or xenobiotics. Therefore, appropriate repair is 
essential in maintaining healthy liver architecture and function (Kuntz et al., 
2008). Repair of damaged liver is a complex wound healing process that 
engages a range of resident and infiltrating cell types in the liver and is 
generally accompanied by some level of fibrosis. While successful liver repair 
ends with fibrosis resolution, repetitive injury and repair generally leads to 
sustained fibrosis (Friedman, 2008b). Liver fibrosis/cirrhosis is commonly 
associated with diseases such as NASH and HCC, which not only affects liver 
function but also limits the treatment options of these diseases (Bataller et al., 
2005, Friedman, 2008b). Therefore, developing antifibrotic therapies is urged 
to improve the clinical outcomes. Since mounting clinical and experimental 
evidences support that fibrosis and even cirrhosis are reversible, understanding 
the mechanisms underlying hepatic fibrosis is fundamental to facilitate the 
research and development of antifibrotic therapies (Bataller et al., 2005, 
Friedman et al., 2006). Despite the tremendous increase in knowledge of the 
molecular and cellular basis of hepatic fibrosis over years, in terms of 
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proteins, signaling pathways and cell types participating in hepatic fibrosis 
development, the precise mechanism of fibrosis is incompletely understood.  
The identification of HSC as the main collagen-producing cell type was a big 
breakthrough in understanding the mechanism of hepatic fibrosis. Activated 
HSCs are only present in injured but not healthy liver (Bataller et al., 2005, 
Kisseleva et al., 2011). As we observed significantly more activated HSCs in 
c-Jun null mouse embryos, we particularly investigated the relevance of c-
JUN in HSC activation and hepatic fibrosis. Our study shows for the first time 
that c-JUN is directly involved in HSC activation and hepatic fibrosis 
development. Most strikingly, we have also found that c-JUN plays contrary 
roles in different liver cell types in regulating HSC activation and hepatic 
fibrosis progression. 
5.2.1 c-JUN actions in HSCs promotes hepatic fibrosis progression and HSC 
activation  
To investigate the direct effect of c-JUN in HSC activation and hepatic 
fibrosis progression, we specifically inactivated c-JUN in activated HSCs and 
examined fibrosis progression by chronic CCl4 injection. Interestingly, HSC-
specific c-JUN deletion resulted in severely increased fibrosis progression as 
compared to the control genotype mice. Moreover, the increased fibrosis was 
also accompanied by significantly more activated HSCs as determined by 
classical activated HSC markers. These results suggest that c-JUN functions to 




The molecular mechanism of how c-JUN functions in HSC to restrict its own 
activation is unknown. HSC activation occurs as a result of a complex 
network of paracrine and autocrine signaling which is stimulated by liver 
injury. The factors involved in these paracrine and autocrine signaling in 
injured livers include cytokines (e.g. TGF-β, TNF-α), growth factors (e.g. 
PDGF, EGF) and Hh ligands (e.g. Shh, Ihh) etc. (Friedman, 2008a, Omenetti 
et al., 2011). Therefore, it is likely that c-JUN acts to regulate HSC activation 
by targeting signaling pathways related to these factors. Serendipitously, we 
found that c-JUN can down-regulate Gli2 transcription. Gli2 is a Hh-regulated 
transcription factor at the distal end of the Hh signaling cascade and functions 
to control transcription of the Hh-responsive genes (Choi et al., 2011, 
Omenetti et al., 2011). This exciting finding suggests a novel mechanism to 
modulate Hh signaling activity by c-JUN. Previous study has reported the 
regulation of Gli2 transcription by TGF-β (Dennler et al., 2007), highlighting 
the existence of the 'non-canonical' Hh signaling. Our finding that c-JUN can 
suppress Gli2 abundance has thus led to a hypothesis that c-JUN may regulate 
HSC activation by intervening via the Hh signaling arm in HSC. This 
hypothesis has been further corroborated by detection of high levels of Hh 
pathway components (Ihh and Gli2 proteins) in the c-Jun-/- embryos.  
Liver injury can trigger the production of Hh ligands thereby activating Hh 
signaling rapidly in HSCs. Initiation of Hh signaling in HSCs can be via both 
autocrine and paracrine mechanisms depending on the source of the Hh 
ligands, as HSCs as well as other liver parenchymal and nonparenchymal cells 
can produce active Hh ligands during liver injury. Active Hh signaling in HSC 
is crucial for its viability and growth (Omenetti et al., 2011). Therefore, 
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modulating Hh signaling in HSCs can be an efficient mechanism to regulate 
HSC accumulation and activity during liver injury and repair. Furthermore, 
once activated, Hh signaling tends to auto-amplify its activation thus further 
augmenting the activated HSC population. However, overactivation of Hh 
signaling also promotes fibrogenesis during liver injury and repair (Omenetti 
et al., 2011). Taken together, our data strongly imply a potential mechanism 
for c-JUN to regulate HSC activation as well as hepatic fibrosis progression 
through constraining the active Hh signaling in the HSCs. Further 
investigation is needed to justify this model. 
5.2.2 Crosstalk between c-JUN and Hh signaling in other tissue 
Both c-JUN and several Hh pathway components (Ptc, Smo, Gli1 and Gli2) 
have been strongly implicated in skin carcinogenesis (Hahn et al., 1996, 
Johnson et al., 1996b, Xie et al., 1998, Grachtchouk et al., 2000, Nilsson et 
al., 2000, Angel et al., 2001, Zenz et al., 2006). Two studies have already 
built a link between c-JUN and Hh signaling in the skin cells (Laner-
Plamberger et al., 2009, Schnidar et al., 2009). By in vitro assays, c-JUN has 
been shown as a direct target of both Gli1 and Gli2 and can cooperate with 
Gli1/2 at the chromatin level to regulate a subset of Gli target gene expression 
in human keratinocytes. Moreover, physical interaction of the N-terminal 
phosphorylated c-JUN with Gli2 but not with Gli1 has been reported. In fact, 
the oncogenic transformation by simultaneous activation of EGFR and Gli1/2 
requires c-JUN. Unfortunately, in both studies, Gli1 and Gli2 were either 
expressed under doxycycline-inducible promoter or transiently overexpressed. 
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Hence, it is not possible to assess whether c-JUN can downregulate Gli2 
expression in those experimental settings. 
We have identified that c-JUN can downregulate Gli2 transcription and there 
are remarkably high levels of Gli2 in c-JUN null embryos. Thus, in 
conjunction with the above mentioned findings that c-JUN is a direct target of 
Gli2 and can cooperate with Gli2 to regulate certain target gene expression, 
there is a strong implication of some auto-regulatory loop between c-JUN and 
Gli2. Such an auto-regulatory loop exists between c-JUN and EGFR: c-JUN 
can positively regulate EGFR transcription while EGFR can activate c-JUN 
via MAPK signaling (Zenz et al., 2003, Zenz et al., 2006). Furthermore, both 
c-JUN and Hh signaling have been identified to participate in PH-induced 
liver regeneration. Nevertheless, the functions of c-JUN and Hh signaling in 
liver regeneration have been attributed to different liver cell types 
(parenchymal cells vs. non-parenchymal cells). Interestingly, inhibition of 
either pathway has resulted in impaired liver regeneration (Behrens et al., 
2002, Swiderska-Syn et al., 2014). Hence It is of crucial importance to 
elucidate the functional relationship between c-JUN and Hh signaling, at least 
in the skin and liver. 
5.2.3 c-JUN plays a dual role in HSC activation and fibrogenesis 
Hepatic repair and fibrosis development engage almost all the cell types in the 
liver. Both hepatocytes and hematopoietic cells (such as Kupffer cells) are 
found to be important in activating HSCs and facilitating fibrosis development 
(Bataller et al., 2005, Friedman, 2008a, Friedman, 2008b). ROS released from 
the dead/dying hepatocytes and pro-inflammatory cytokines (especially TGF-
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β) produced from resident/infiltrating inflammatory cells are all potent 
inducers for HSC activation (Friedman, 2000, Friedman, 2008a, Friedman, 
2008b).  
We have thus inactivated c-JUN specifically in hepatocytes and hematopoietic 
cells but not in HSCs to investigate the effect of c-JUN on HSC activation and 
fibrogenesis in a non-cell-autonomous manner. Surprisingly, we observed a 
completely contrary phenotype as both HSC activation and fibrosis 
progression were significantly reduced in livers where c-JUN has been 
inactivated in hepatocytes and hematopoietic cells. Apparently, c-JUN plays a 
dual role in hepatic fibrosis development and in different liver cell types, i.e. 
anti-fibrotic in HSCs and pro-fibrotic in hepatocytes and hematopoietic cells 
(Figure 30).  
 
 
Figure 30. c-JUN plays a dual role in hepatic fibrosis development and in 
different liver cell types 
c-JUN  exerts anti-fibrotic function in HSC: loss of c-Jun in HSCs promotes fibrosis 
development and enhances HSC activation. c-JUN exerts pro-fibrotic function in 
hepatocytes and hematopoietic cells: loss of c-Jun in hepatocytes and hematopoietic 




The phenotype of one protein exhibiting opposite functions in different cell 
types has been reported before, examples like JNK, NFκB and EGFR have 
been demonstrated to play an anti-tumorigenic function in hepatocytes but a 
pro-tumorigenic function in Kupffer cells in the DEN-induced HCC model 
(Maeda et al., 2005, Das et al., 2011, Lanaya et al., 2014). These studies 
together with our findings highlight the importance of the microenvironment, 
paracrine signaling and interactions between different cell types in liver 
pathology. This therefore adds the complexity to the molecular basis of how 
different liver cell types contribute to hepatic fibrosis development. 
5.2.4 c-JUN functions in hepatocytes 
Liver damage usually causes hepatocyte death followed by proliferation to 
compensate for the loss of liver parenchyma. Historically, the impact of c-
JUN in the liver has been emphasized particularly on its roles in regulating 
both hepatocyte survival and proliferation. 
Many studies have underscored the function of c-JUN in promoting 
hepatocyte survival especially during early stages of liver pathogenesis. 
Absence of c-JUN in hepatocytes invariably resulted in markedly increased 
hepatocyte death upon various pathological stimuli including DEN, TNF-α, 
Con A and sustained endoplasmic reticulum stress (Eferl et al., 2003a, 
Hasselblatt et al., 2007, Fuest et al., 2012, Min et al., 2012). The mechanisms 
by which c-JUN promotes hepatocyte survival are largely stimulus dependent: 
such as by antagonizing p53 and its pro-apoptotic target noxa upon TNF-α 
treatment (Eferl et al., 2003a) or by induction of nos2 expression and 
subsequent nitric oxide production upon Con A treatment (Hasselblatt et al., 
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2007). In our model, CCl4 is used as the pathological stimulus. Administration 
of CCl4 induces inflammation and thereby activates the release of 
inflammatory mediators such as TNF-α and nitric oxide (Morio et al., 2001). 
As both TNF-α and nitric oxide are directly associated with c-JUN functions 
in promoting hepatocyte survival, we can expect a higher grade of hepatocyte 
injury and death in the c-Junf/f;Mx-Cretg mice, which will be assessed in the 
future. 
Increased hepatocyte death is generally considered to contribute to the hepatic 
accumulation of the activated inflammatory cells as well as activated HSCs, 
which leads to increased fibrosis (Syn et al., 2009). Whereas, on the contrary, 
we have observed less activated HSCs and less fibrosis in the c-Junf/f;Mx-Cretg 
mice. These data impling that (1) there may be other inflammatory mediator(s) 
that is/are regulated by c-JUN in hepatocyte and/or hematopoietic cells which 
play(s) critical role; (2) c-JUN's role in hematopoietic cells is more important 
in regulating HSC activation and fibrogenesis. 
5.2.5 c-JUN activity in hematopoietic cells 
In a DEN-induced mouse HCC model, inactivation of certain genes such as 
JNK, NFκB or EGFR in hepatocyte alone (by using Albumin-Cre) or in both 
hepatocytes and hematopoietic cells (by using Mx-Cre) have resulted in 
completely opposite effect in HCC progression (Maeda et al., 2005, Das et al., 
2011, Lanaya et al., 2014), emphasizing the decisive role of the hematopoietic 
cells in liver pathogenesis. However, several studies inactivating c-JUN in 
either hepatocyte alone (by using Alfp-Cre) or in both hepatocytes and 
hematopoietic cells (by using Mx-Cre) under various pathological conditions 
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have exhibited identical phenotypes. These include liver regeneration 
stimulated by PH (Behrens et al., 2002, Stepniak et al., 2006), acute liver 
hepatitis caused by Con A (Hasselblatt et al., 2007) and liver carcinogenesis 
initiated by DEN (Eferl et al., 2003a). Moreover, although whole body c-JUN 
knockout caused extensive apoptosis of both fetal hepatocytes and 
hematopoietic cells, the c-Jun-/- fetal liver cells were able to reconstitute all 
hematopoietic compartments (spleen, thymus and bone marrow) of lethally 
irradiated adult recipient mice (Eferl et al., 1999).  
In order to dissect the compound pro-fibrotic effect of c-JUN in both 
hepatocytes and hematopoietic cells during hepatic fibrosis progression, it will 
be necessary to inactivate c-JUN specifically in either hepatocyte or 
hematopoietic cell. Yet more experiments such as the measurement of hepatic 
cell death and cytokine production are also needed to determine how c-JUN 
functions in hepatocytes and hematopoietic cells affects HSC activation. 
5.2.6 JNK signaling in hepatic fibrosis  
JNKs (JNK1 and JNK2) have been identified to play key roles in various 
types of liver diseases (e.g. NAFLD, NASH and HCC) as well as diseases 
associated with liver functions (e.g. insulin resistance and obesity) (Seki et al., 
2012). Since the above mentioned pathological conditions are usually 
accompanied with chronic liver injury and certain degrees of liver fibrosis, 
some studies have investigated the direct effect of JNKs in hepatic fibrosis in 
the CCl4 and/or BDL models and found that JNK1 plays a more predominant 
role in liver repair and fibrogenesis (Kluwe et al., 2010, Hong et al., 2013, 
Zhao et al., 2014).  
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Activated JNKs are expressed in hepatocytes, inflammatory cells and 
myofibroblasts in humans and mice with chronic liver diseases (Seki et al., 
2012, Cubero et al., 2015). Interestingly, mice with whole body knockout of 
JNK1 exhibited significant protection whereas mice with hepatocyte-specific 
knockout of JNK1 were not protected from liver injury and fibrosis compared 
to wild type mice in both CCl4 and BDL-induced fibrosis models. It has thus 
been suggested that JNK1 functions in the non-parenchymal cells promotes 
HSC activation and fibrogenesis (Zhao et al., 2014). Consistently, JNK1 in 
hematopoietic cells also promotes HCC development (Das et al., 2011). c-
JUN being the main downstream effector of the JNK signaling pathway and a 
dual regulator in different liver cell types in fibrosis progression, its activity in 
the liver should be investigated together with JNKs. Nevertheless, c-JUN can 
function in a JNK-dependent and -independent manner and even show 
opposite effect in certain circumstances such as in regulating HCC 
development. Mice with hepatocyte-specific deletion of c-JUN protects 
against (Eferl et al., 2003a, Min et al., 2012) whereas mice with hepatocyte-
specific deletion of JNK1 promotes liver tumor development (Das et al., 
2011) in the DEN-induced HCC model. Hence the functions of c-JUN and 
JNK in hepatic fibrosis needs to be carefully examined especially in different 
liver cell types.  
5.2.7 Clinical significance and future direction 
As activated HSCs are the major collagen producing cells, their cell fate 
(quiescence, activation, senescence or death) can affect the degree of hepatic 
fibrosis. Thus HSC is currently the primary target in antifibrotic therapy 
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development (Kisseleva et al., 2011). Identification of targetable molecules 
and pathways responsible for HSC activation would be beneficial in exploring 
effective antifibrotic therapies. We have discovered that c-JUN can regulate 
HSC activation in both cell-autonomous and non-cell-autonomous manner. 
Our data suggest that molecules and pathways associated with c-JUN (e.g. 
JNK and Hh) are attractive druggable targets that may help to slow or halt the 
fibrosis progression. In addition, our data has also raised the importance that 
different cell types participate differently in the fibrosis development. Hence, 
an effective antifibrotic therapy should meet both criteria: targeting the right 
molecule(s) and in the right cell type(s). Taken these considerations, using 
commercially available drugs such as Hh inhibitors to treat the fibrotic mice of 
different c-Jun genotypes may help to identify effective antifibrotic molecules 
as well as to differentiate the antifibrotic effect in different liver cell types. 
Furthermore, whether inactivation of c-Jun in different liver cell types would 
affect hepatic fibrosis reversion is another interesting question to be 

















Figure 31. Mechanistic insights into the function of c-JUN at both the molecular 




This study has investigated the functions of c-JUN at both the molecular and 
physiological levels (Figure 31). In the first part, we have identified, validated 
and analyzed genes that are regulated by c-JUN and JNP under both basal and 
stressed conditions in a whole genome scale. We have thus uncovered many 
novel genes and several potential biological pathways that may be regulated 
by c-JUN and/or JNP. This study has contributed to a novel view that the N-
terminal unphosphorylated c-JUN can function as a transcription factor and is 
sufficient to regulate its target gene expression; further advancing the 
knowledge of how c-JUN functions in a JNP-dependent and -independent 
manner and influences the cellular behaviors in response to stimuli such as 
genotoxic stresses.  
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In the second part, we have specifically investigated c-JUN functions in liver 
fibrosis, as the top pathway identified from the first part. Though c-JUN is 
well-known for its role in liver physiology including embryonic 
hepatogenesis, adult liver regeneration, inflammatory liver diseases and HCC 
initiation, its role in liver fibrosis is relatively unknown. Till date, no studies 
have reported any effect of c-JUN on hepatic fibrosis yet. Our study shows for 
the first time that c-JUN plays a dual role in different liver cell types in HSC 
activation and hepatic fibrosis development. More importantly, our study has 
provided a better understanding of the role of c-JUN in fibrosis initiation and 
progression, by the use of the inducible and cell type-specific loss-of-function 
models. The advantages of these models are (1) it allows the mice to develop 
normally in the presence of c-JUN until the induction of fibrosis; (2) it only 
inactivates c-JUN in certain cell type(s) while keeping c-JUN intact in the 
remaining of the body; (3) it examines c-JUN functions at the physiological 
level as studies using transgenic or overexpression models may reflect the 
functions of c-JUN at rather a supraphysiological level. The complete 
mechanism of how c-JUN regulates HSC activation and fibrosis progression 
has yet to be elucidated, but the data shown here strongly point to the crosstalk 
between c-JUN and Hh signaling as a potential mechanism in this biological 
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